

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003856

International filing date: 04 February 2005 (04.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/542,210  
Filing date: 04 February 2004 (04.02.2004)

Date of receipt at the International Bureau: 14 March 2005 (14.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1292462

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 04, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/542,210**

**FILING DATE: February 04, 2004**

**RELATED PCT APPLICATION NUMBER: PCT/US05/03856**



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).


Express Mail Label No. EV 317113923 US

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
Sami	Saribas	Philadelphia, PA			
David	Hakes	Willow Grove, PA			
<input checked="" type="checkbox"/> Additional inventors are being named on the 1 separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHOD OF REFOLDING MAMMALIAN GLYCOSYLTRANSFERASES					
Direct all correspondence to: <b>CORRESPONDENCE ADDRESS</b>					
<input checked="" type="checkbox"/> Customer Number <span style="border: 1px solid black; padding: 2px 20px;">20350</span>					
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <span style="border: 1px solid black; padding: 0 10px;">72</span> <input type="checkbox"/> CD(s), Number <span style="border: 1px solid black; padding: 0 10px;"></span>					
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets <span style="border: 1px solid black; padding: 0 10px;">12</span> <input type="checkbox"/> Other (specify) <span style="border: 1px solid black; padding: 0 10px;"></span>					
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <b>20-1430</b>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<div style="text-align: right;">FILING FEE Amount (\$)</div> <div style="border: 1px solid black; width: 100px; margin: 0 auto; text-align: center;">80</div>					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: .					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE



Date 02/04/2004

TYPED or PRINTED NAME

Beth L. Kelly

REGISTRATION NO. 51,868

(if appropriate)

Docket Number: 019957-016800US

TELEPHONE 415-576-0200

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

**PROVISIONAL APPLICATION COVER SHEET**  
*Additional Page*

PTO/SB/16 (08-03)


Docket Number    019957-016800US		
INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Scott Karl F. Daniel J. Shawn	Willett Johnson Bezila DeFrees	Doylestown, PA Hatboro, PA Philadelphia, PA North Wales, PA


[Page 2 of 2]

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	
		Filing Date	February 4, 2004
		First Named Inventor	Saribas, Sami
		Art Unit	
		Examiner Name	
Total Number of Pages in This Submission	95	Attorney Docket Number	019957-016800US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input checked="" type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Return Postcard; Prov. Apl. Patent Cover Sheet with fee auth. to Dep. Acct. 20-1430 (2 pgs., 2 copies); Appl. Data Sheet (5 pgs.); unnumbered cover sheet (1 pg.); provisional pat. appl. including spec., claims and abst. (72 pgs.); and Figures 1-12 (12 sheets).
Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	Townsend and Townsend and Crew LLP Beth L. Kelly Reg. No. 51,868	
Signature		
Date	02/04/2004	

CERTIFICATE OF MAILING		
Express Mail Label: EV 317113923 US		
I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date 02/04/2004 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450		
Typed or printed name	Dana Kane	
Signature		Date 02/04/2004

Attorney Docket No.: 019957-016800US  
Client Reference No.: NEO00255 PR

**PROVISIONAL**

**PATENT APPLICATION**

**METHODS OF REFOLDING MAMMALIAN  
GLYCOSYLTRANSFERASES**

Inventor(s): Sami Saribas, a citizen of Turkey, residing at  
424 E. Church Lane  
Philadelphia, PA 19144

David Hakes, a citizen of The United States, residing at  
14 Fern Avenue  
Willow Grove, PA 19090

Scott Willett, a citizen of The United States, residing at  
3820 Comley Circle  
Doylestown, PA 19801

Karl F. Johnson, a citizen of The United States, residing at  
5320 Ivystream Road  
Hatboro, PA 19040

Daniel James Bezila, a citizen of The United States, residing at  
715 Red Lion Road, 2nd Floor  
Philadelphia, PA 19115

Shawn DeFrees, a citizen of The United States, residing at  
126 Filly Drive  
North Wales, PA 19454

Assignee: Neose Technologies, Inc.  
102 Witmer Road  
Horsham, PA, 19044

Entity: Small  
TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200

## METHODS OF REFOLDING MAMMALIAN GLYCOSYLTRANSFERASES

### FIELD OF INVENTION

5 [0001] The present invention provides methods of refolding mammalian glycosyltransferases that have been produced in bacterial cells, including glycosyltransferase mutants that have enhanced ability to be refolded, and methods to use such refolded glycosyltransferases. The invention also provides methods of refolding more than one glycosyltransferase in a single vessel, methods to use such refolded glycosyltransferases, and  
10 reaction mixtures comprising the refolded glycosyltransferases.

### BACKGROUND OF THE INVENTION

[0002] Eukaryotic organisms synthesize oligosaccharide structures or glycoconjugates, such as glycolipids or glycoproteins, that are commercially and therapeutically useful. *In vitro* synthesis of oligosaccharides or glycoconjugates can be carried out using recombinant  
15 eukaryotic glycosyltransferases. The most efficient method to produce recombinant eukaryotic glycosyltransferases for oligosaccharide synthesis is to express the protein in bacteria. However, in bacteria, many eukaryotic glycosyltransferases are expressed as insoluble proteins in bacterial inclusion bodies, and yields of active protein from the inclusion bodies can be very low. Thus, there is a need for improved methods to produce eukaryotic  
20 glycosyltransferases in bacteria. The present invention solves this and other needs.

### BRIEF SUMMARY OF THE INVENTION

[0003] The present invention provides improved methods to refold insoluble eukaryotic glycosyltransferases in an active form and also provides glycosyltransferases, *e.g.*, N-acetylglucosaminyltransferase I (GnTI) enzymes that have enhanced refolding properties.

25 [0004] In one aspect, the invention provides a recombinant eukaryotic N-acetylglucosaminyltransferase I (GnTI) enzyme, that has been mutated to replace an unpaired cysteine residue with an amino acid that enhances refolding of the enzyme from an insoluble precipitate, *e.g.*, bacterial inclusion bodies. The GnTI enzyme includes at least the catalytic domain of the GnTI enzyme. The GnTI enzyme is biologically active, *i.e.*, able to catalyze  
30 the transfer of a donor substrate to an acceptor substrate.

[0005] In one embodiment, the GnTI enzyme is a human protein. Some mutations of the CYS121 residue in human GnT1 enhance refolding. Those mutants include *e.g.*, CYS121SER mutation, a CYS121ALA mutation, CYS121ASP mutation, and a double mutant, ARG120ALA, CYS121HIS. Representative sequences of GnT1 mutants are shown in Figures 7-11. In other eukaryotes, *e.g.*, similar mutations of an unpaired cysteine residue, CYS123, enhance refolding of the GnT1 enzyme.

[0006] In another embodiment, the GnTI enzyme also includes an amino acid tag, *e.g.*, a maltose binding protein (MBP), a polyhistidine tag, a glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope.

[0007] In another aspect, the invention provides nucleic acids encoding a recombinant eukaryotic GnTI enzyme, that has been mutated to replace an unpaired cysteine residue with an amino acid that enhances refolding of the enzyme from an insoluble precipitate, *e.g.*, bacterial inclusion bodies. As above, the encoded GnT1 enzyme includes at least the catalytic domain of the GnT1 enzyme, and is biologically active, *i.e.*, able to catalyze the transfer of a donor substrate to an acceptor substrate.

[0008] In one embodiment, the nucleic acids encode a human GnTI enzyme. Some mutations of the CYS121 residue in human GnT1 enhance refolding. Those mutants include *e.g.*, CYS121SER mutation, a CYS121ALA mutation, CYS121ASP mutation, and a double mutant, ARG120ALA, CYS121HIS. Representative nucleic acids sequences of GnT1 mutant proteins and nucleic acids are shown in Figures 7-11. In other eukaryotes, *e.g.*, similar mutations of an unpaired cysteine residue, CYS123, enhance refolding of the GnT1 enzyme.

[0009] In a further embodiment, the encoded GnTI enzyme also includes an amino acid tag, *e.g.*, a maltose binding protein (MBP), a polyhistidine tag, a glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope.

[0010] The invention also includes expression vectors that include the mutated GnT1 nucleic acids, host cells that include the GnT1 expression vectors, and methods of producing the mutated GnT1 enzymes using the host/expression vector system.

[0011] In another embodiment, the invention provides a method of adding N-acetylglucosamine residues to an acceptor molecule with a terminal mannose residue, by contacting the acceptor molecule with an activated N-acetylglucosamine molecule and a



eukaryotic GnTI enzyme that has been mutated to enhance refolding. The acceptor molecule can be *e.g.*, a polysaccharide, an oligosaccharide, a glycolipid, or a glycoprotein.

[0012] In another aspect, the invention provides a method of refolding at least two insoluble, recombinant eukaryotic glycosyltransferase proteins in a single vessel, by contacting the glycosyltransferases with a refolding buffer that includes a redox couple. After refolding, at least two of the refolded glycosyltransferases have biological activity, *e.g.*, are able to catalyze the transfer of a donor substrate to an acceptor substrate.

[0013] The refolding buffer can also include a detergent, or a chaotropic agent, or arginine, or PEG. In some embodiments the pH of the refolding buffer is between 6.0 and 10.0. In one embodiment, the pH of the refolding buffer is between 6.5 and 8.0. In another embodiment, the pH of the refolding buffer is between 8.0 and 9.0.

[0014] In another embodiment, the glycosyltransferases include an amino acid tag, *e.g.*, a maltose binding protein (MBP), a polyhistidine tag, a glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope

[0015] In one embodiment, more than one glycosyltransferase from an N-linked glycan biosynthetic pathway are refolded together.

[0016] In one embodiment, a sialyltransferase is refolded with another glycosyltransferase using the methods of the invention.

[0017] In one embodiment, an N-acetylglucosaminyltransferase is refolded with another glycosyltransferase using the methods of the invention.

[0018] In one embodiment, a galactosyltransferase is refolded with another glycosyltransferase using the methods of the invention.

[0019] In another embodiment, a sialyltransferase, an N-acetylglucosaminyltransferase, and a galactosyltransferase are refolded together in a single vessel using the methods of the invention.

[0020] In one embodiment, more than one glycosyltransferase from an O-linked glycan biosynthetic pathway are refolded together.

[0021] The present invention also provides a reaction mixture including a recombinant eukaryotic GnTI enzyme, that has been mutated to replace an unpaired cysteine residue with an amino acid that enhances refolding of the enzyme from an insoluble precipitate, *e.g.*,

bacterial inclusion bodies and at least one other glycosyltransferase that have been refolded in the same vessel. The second glycosyltransferase can be *e.g.*, a sialyltransferase or a galactosyltransferase. In one embodiment, the reaction mixture includes the mutated eukaryotic GnT1 enzyme, a sialyltransferase, and a galactosyltransferase. The reaction mixtures can be used with an acceptor molecule with a donor sugar, to produce *e.g.*, a polysaccharide, an oligosaccharide, a glycolipid, or a glycoprotein.

[0022] In another aspect, the invention provides a method of refolding an insoluble recombinant eukaryotic sialyltransferase, by (a) solubilizing the sialyltransferase; and then (b) contacting the soluble sialyltransferase with a refolding buffer including a redox couple. The refolded sialyltransferase is biologically active and catalyzes the transfer of sialic acid from a donor substrate to an acceptor substrate. In one embodiment, the refolded sialyltransferase is dialyzed or diafiltered.

[0023] The refolding buffer can also include a detergent, or a chaotropic agent, or arginine. In some embodiments the pH of the refolding buffer is between 6.0 and 10.0. In one embodiment, the pH of the refolding buffer is between 6.5 and 8.0. In another embodiment, the pH of the refolding buffer is between 8.0 and 9.0.

[0024] In one embodiment, the redox couple in the refolding buffer is reduced glutathione/oxidized glutathione (GSH/GSSG). In a further embodiment, the molar ratio of GSH/GSSG is between 100:1 and 1:10. In a preferred embodiment, the molar ratio of GSH/GSSG is 10:1. In a still further embodiment, the refolding buffer comprises about 0.02-10 mM GSH, 0.005-10 mM GSSG, 0.005-10 mM lauryl maltoside, 50-250 mM NaCl, 2-10 mM KCl, 0.01-0.05% PEG 3350, and 150-550 mM L-arginine.

[0025] In another embodiment, the sialyltransferase includes an amino acid tag *e.g.*, maltose binding protein (MBP), a polyhistidine tag, a glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope. In a further embodiment, the sialyltransferase is purified using a tag binding molecule that binds to the amino acid tag. For example, the amino acid tag can be MBP and the tag binding molecule can be amylose, maltose, or a cyclodextrin.

[0026] In another embodiment, the refolded sialyltransferase catalyzes the transfer of sialic acid from CMP-sialic acid to a glycoprotein.

[0027] In a further embodiment, the refolded sialyltransferase catalyzes the transfer of 10KPEG or 20K PEG from CMP-SA-PEG(10 kDa) or CMP-SA-PEG(20 kDa) to a glycoprotein.

[0028] In another embodiment, the sialyltransferase is rat liver ST3GalIII.

5 [0029] In another aspect, the invention provides a method of adding a sialyl moiety to a glycoprotein, by contacting the glycoprotein with CMP-sialic acid with a refolded mammalian sialyltransferase that was refolded using the methods disclosed herein.

[0030] In another aspect, the invention provides a method of adding a PEG moiety to a glycoprotein, the method comprising by contacting the glycoprotein with CMP-SA-PEG(10  
10 kDa) or CMP-SA-PEG(20 kDa) and a refolded mammalian sialyltransferase that was refolded using the methods disclosed herein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 provides the buffer conditions tested in refolding MBP-ST3GalIII from bacterial inclusion bodies. The activity of the refolded enzymes is also provided.

15 [0032] Figure 2 provides an elution profile of refolded and dialyzed MBP-ST3GalIII from an amylose column.

[0033] Figure 3 provides the ST3GalIII activities of the elution fractions from the amylose column.

[0034] Figure 4 provides the results of an assay of glycoPEGylation of transferrin using  
20 purified refolded MBP-ST3GalIII. Lanes are as follows: (1) MW markers [250, 148, 98, 64, 50 kD]; (2) Control asialotransferrin with no enzyme, indicated by solid arrow; (3) transferrin-SA-PEG (20 kDa) production with Fraction #5, products indicated by arrowhead; (4) transferrin-SA-PEG (20 kDa) production with Fraction # 6, products indicated by arrowhead; (5) Purified, refolded MBP-ST3GalIII Fr # 6, indicated by dotted arrow; (6)  
25 MW markers; (7) same as 2; (8) transferrin-SA-PEG (10 kDa) production with Fr # 4, products indicated by brackets; and (9) transferrin-SA-PEG (10 kDa) production with Fr # 5, products indicated by brackets.

[0035] Figure 5 provides the results of an assay of GlycoPEGylation of EPO using the refolded SuperGlycoMix. Lanes are as follows: (1) MW markers, SeeBlue2  
30 Invitrogen,(250, 148, 98, 64, 50, 36, 22, 16, 6 kD); (2) Positive control with EPO, + NSO

expressed GalT1, BV GnT1, *Aspergillus* ST3GalIII and sugar nucleotides; (3) Negative control, Same as 2 without UDP-GlcNAc; (4) EPO, Purified and separately refolded MBP-GalT1( $\Delta$ 129) C342T, Refolded MBP-GnT1( $\Delta$ 103), and *Aspergillus niger* expressed ST3GalIII; (5) EPO, SuperGlycoMix (mixture of MBP-ST3GalIII, MBP-GalT1( $\Delta$ 129) C342T, MBP-GnT1( $\Delta$ 103)C123A and sugar nucleotides.

[0036] Figure 6 provides an alignment of a human GnT1 amino acid sequence (top line, NP\_002397) and a rabbit GnT1 amino acid sequence (bottom line, P27115). The conserved unpaired cysteines are underlined and in bold text.

[0037] Figure 7 provides the amino acid sequence of a GnT1 Cys121Ser mutant and a nucleic acid sequence that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrrsldkllh..., where the bold residue is mutated from the wild-type cysteine.

[0038] Figure 8 provides the amino acid sequence of a GnT1 Cys121Asp mutant and a nucleic acid sequence that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrrldkllh..., where the bold residue is mutated from the wild-type cysteine.

[0039] Figure 9 provides the amino acid sequence of a GnT1 Cys121Thr mutant and a nucleic acid sequence that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrrtdkllh..., where the bold residue is mutated from the wild-type cysteine.

[0040] Figure 10 provides the amino acid sequence of a GnT1 Cys121Ala mutant and a nucleic acid sequence that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is representative of mammalian GnT1 proteins with the following unpaired cysteine mutation: ...stvrraldkllh..., where the bold residue is mutated from the wild-type cysteine.

[0041] Figure 11 provides the amino acid sequence of a GnT1 Arg120Ala, Cys121His mutant and a nucleic acid sequence that encodes the mutant GnT1 protein. The amino acid sequence depicted begins with amino acid residue 104 of the full length human protein and is

representative of mammalian GnT1 proteins with the following double mutation:  
...stv**ra**hldkllh..., where the bold residue is mutated from the wild-type cysteine.

[0042] Figure 12 provides the amino acid sequence of rat liver ST3GalIII. The underlined and italicized sequence was deleted during cloning.

5

## DEFINITIONS

[0043] The recombinant glycosyltransferase proteins of the invention are useful for transferring a saccharide from a donor substrate to an acceptor substrate. The addition generally takes place at the non-reducing end of an oligosaccharide or carbohydrate moiety on a biomolecule. Biomolecules as defined here include but are not limited to biologically  
10 significant molecules such as carbohydrates, proteins (*e.g.*, glycoproteins), and lipids (*e.g.*, glycolipids, phospholipids, sphingolipids and gangliosides).

The following abbreviations are used herein:

Ara = arabinosyl;

Fru = fructosyl;

15

Fuc = fucosyl;

Gal = galactosyl;

GalNAc = N-acetylgalactosylamino;

Glc = glucosyl;

GlcNAc = N-acetylglucosylamino;

20

Man = mannosyl; and

NeuAc = sialyl (N-acetylneuraminy)

FT or FucT = fucosyltransferase\*

ST = sialyltransferase\*

GalT = galactosyltransferase\*

25

[0044] Arabic or Roman numerals are used interchangeably herein according to the naming convention used in the art to indicate the identity of a specific glycosyltransferase (*e.g.*, FTVII and FT7 refer to the same fucosyltransferase).

30

[0045] Oligosaccharides are considered to have a reducing end and a non-reducing end, whether or not the saccharide at the reducing end is in fact a reducing sugar. In accordance with accepted nomenclature, oligosaccharides are depicted herein with the non-reducing end on the left and the reducing end on the right.

[0046] All oligosaccharides described herein are described with the name or abbreviation for the non-reducing saccharide (*e.g.*, Gal), followed by the configuration of the glycosidic bond ( $\alpha$  or  $\beta$ ), the ring bond, the ring position of the reducing saccharide involved in the bond, and then the name or abbreviation of the reducing saccharide (*e.g.*, GlcNAc). The linkage between two sugars may be expressed, for example, as 2,3, 2 $\rightarrow$ 3, or (2,3). Each saccharide is a pyranose or furanose.

[0047] The term “sialic acid” refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N-acetyl-neuraminic acid (2-keto-5-acetamido-3,5-dideoxy-D-glycero-D-galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA). A second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group of NeuAc is hydroxylated. A third sialic acid family member is 2-keto-3-deoxy-nonulosonic acid (KDN) (Nadano *et al.* (1986) *J. Biol. Chem.* **261**: 11550-11557; Kanamori *et al.*, *J. Biol. Chem.* **265**: 21811-21819 (1990)). Also included are 9-substituted sialic acids such as a 9-O-C<sub>1</sub>-C<sub>6</sub> acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetyl-Neu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-Neu5Ac. For review of the sialic acid family, *see, e.g.*, Varki, *Glycobiology* **2**: 25-40 (1992); *Sialic Acids: Chemistry, Metabolism and Function*, R. Schauer, Ed. (Springer-Verlag, New York (1992)). The synthesis and use of sialic acid compounds in a sialylation procedure is disclosed in international application WO 92/16640, published October 1, 1992.

[0048] An “acceptor substrate” for a glycosyltransferase is an oligosaccharide moiety that can act as an acceptor for a particular glycosyltransferase. When the acceptor substrate is contacted with the corresponding glycosyltransferase and sugar donor substrate, and other necessary reaction mixture components, and the reaction mixture is incubated for a sufficient period of time, the glycosyltransferase transfers sugar residues from the sugar donor substrate to the acceptor substrate. The acceptor substrate will often vary for different types of a particular glycosyltransferase. For example, the acceptor substrate for a mammalian galactoside 2-L-fucosyltransferase ( $\alpha$ 1,2-fucosyltransferase) will include a Gal $\beta$ 1,4-GlcNAc-R at a non-reducing terminus of an oligosaccharide; this fucosyltransferase attaches a fucose residue to the Gal via an  $\alpha$ 1,2 linkage. Terminal Gal $\beta$ 1,4-GlcNAc-R and Gal $\beta$ 1,3-GlcNAc-R and sialylated analogs thereof are acceptor substrates for  $\alpha$ 1,3 and  $\alpha$ 1,4-fucosyltransferases, respectively. These enzymes, however, attach the fucose residue to the GlcNAc residue of the acceptor substrate. Accordingly, the term “acceptor substrate” is taken in context with the

particular glycosyltransferase of interest for a particular application. Acceptor substrates for additional glycosyltransferases, are described herein.

[0049] A "donor substrate" for glycosyltransferases is an activated nucleotide sugar. Such activated sugars generally consist of uridine, guanosine, and cytidine monophosphate derivatives of the sugars (UMP, GMP and CMP, respectively) or diphosphate derivatives of the sugars (UDP, GDP and CDP, respectively) in which the nucleoside monophosphate or diphosphate serves as a leaving group. For example, a donor substrate for fucosyltransferases is GDP-fucose. Donor substrates for sialyltransferases, for example, are activated sugar nucleotides comprising the desired sialic acid. For instance, in the case of NeuAc, the activated sugar is CMP-NeuAc.

[0050] A "eukaryotic *N*-acetylglucosaminyltransferase I (GnTI or GNTI)" as used herein, refers to a  $\beta$ -1,2-*N*-acetylglucosaminyltransferase I isolated from a eukaryotic organism. The enzyme catalyzes the transfer of *N*-acetylglucosamine (GlcNAc) from a UDP-GlcNAc donor to an acceptor molecule comprising a mannose sugar. Like other eukaryotic glycosyltransferases, GnTI has a transmembrane domain, a stem region, and a catalytic domain.

[0051] An "unpaired cysteine residue" as used herein, refers to a cysteine residue, which in a correctly folded protein (*i.e.*, a protein with biological activity), does not form a disulfide bond with another cysteine residue.

[0052] An "insoluble glycosyltransferase" refers to a glycosyltransferase that is expressed in bacterial inclusion bodies. Insoluble glycosyltransferases are typically solubilized or denatured using *e.g.*, detergents or chaotropic agents or some combination. "Refolding" refers to a process of restoring the structure of a biologically active glycosyltransferase to a glycosyltransferase that has been solubilized or denatured. Thus, a refolding buffer, refers to a buffer that enhances or accelerates refolding of a glycosyltransferase.

[0053] A "redox couple" refers to mixtures of reduced and oxidized thiol reagents and include reduced and oxidized glutathione (GSH/GSSG), cysteine/cystine, cysteamine/cystamine, DTT/GSSG, and DTE/GSSG. (*See, e.g.*, Clark, *Cur. Op. Biotech.* 12:202-207 (2001)).

[0054] The term "contacting" is used herein interchangeably with the following: combined with, added to, mixed with, passed over, incubated with, flowed over, etc.

[0055] The term "PEG" refers to poly(ethylene glycol). PEG is an exemplary polymer that has been conjugated to peptides. The use of PEG to derivatize peptide therapeutics has been demonstrated to reduce the immunogenicity of the peptides and prolong the clearance time from the circulation. For example, U.S. Pat. No. 4,179,337 (Davis *et al.*) concerns non-immunogenic peptides, such as enzymes and peptide hormones coupled to polyethylene glycol (PEG) or polypropylene glycol. Between 10 and 100 moles of polymer are used per mole peptide and at least 15% of the physiological activity is maintained.

[0056] The term "specific activity" as used herein refers to the catalytic activity of an enzyme, *e.g.*, a recombinant glycosyltransferase fusion protein of the present invention, and may be expressed in activity units. As used herein, one activity unit catalyzes the formation of 1  $\mu$ mol of product per minute at a given temperature (*e.g.*, at 37°C) and pH value (*e.g.*, at pH 7.5). Thus, 10 units of an enzyme is a catalytic amount of that enzyme where 10  $\mu$ mol of substrate are converted to 10  $\mu$ mol of product in one minute at a temperature of, *e.g.*, 37 °C and a pH value of, *e.g.*, 7.5.

[0057] "N-linked" oligosaccharides are those oligosaccharides that are linked to a peptide backbone through asparagine, by way of an asparagine-N-acetylglucosamine linkage. N-linked oligosaccharides are also called "N-glycans." All N-linked oligosaccharides have a common pentasaccharide core of Man<sub>3</sub>GlcNAc<sub>2</sub>. They differ in the presence of, and in the number of branches (also called antennae) of peripheral sugars such as N-acetylglucosamine, galactose, N-acetylgalactosamine, fucose and sialic acid. Optionally, this structure may also contain a core fucose molecule and/or a xylose molecule.

[0058] "O-linked" oligosaccharides are those oligosaccharides that are linked to a peptide backbone through threonine, serine, hydroxyproline, tyrosine, or other hydroxy-containing amino acids.

[0059] A "substantially uniform glycoform" or a "substantially uniform glycosylation pattern," when referring to a glycoprotein species, refers to the percentage of acceptor substrates that are glycosylated by the glycosyltransferase of interest (*e.g.*, fucosyltransferase). It will be understood by one of skill in the art, that the starting material may contain glycosylated acceptor substrates. Thus, the calculated amount of glycosylation will include acceptor substrates that are glycosylated by the methods of the invention, as well as those acceptor substrates already glycosylated in the starting material.



[0060] The term “substantially” in the above definitions of “substantially uniform” generally means at least about 60%, at least about 70%, at least about 80%, or more preferably at least about 90%, and still more preferably at least about 95% of the acceptor substrates for a particular glycosyltransferase are glycosylated.

5 [0061] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, *e.g.*, hydroxyproline,  $\gamma$ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have  
10 the same basic chemical structure as a naturally occurring amino acid, *i.e.*, an  $\alpha$  carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, *e.g.*, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (*e.g.*, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical  
15 compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

[0062] “Protein”, “polypeptide”, or “peptide” refer to a polymer in which the monomers are amino acids and are joined together through amide bonds, alternatively referred to as a polypeptide. When the amino acids are  $\alpha$ -amino acids, either the L-optical isomer or the D-  
20 optical isomer can be used. Additionally, unnatural amino acids, for example,  $\beta$ -alanine, phenylglycine and homoarginine are also included. Amino acids that are not gene-encoded may also be used in the present invention. Furthermore, amino acids that have been modified to include reactive groups may also be used in the invention. All of the amino acids used in the present invention may be either the D - or L -isomer. The L -isomers are generally  
25 preferred. In addition, other peptidomimetics are also useful in the present invention. For a general review, *see*, Spatola, A. F., in CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES AND PROTEINS, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983).

[0063] The term “recombinant” when used with reference to a cell indicates that the cell replicates a heterologous nucleic acid, or expresses a peptide or protein encoded by a  
30 heterologous nucleic acid. Recombinant cells can contain genes that are not found within the native (non-recombinant) form of the cell. Recombinant cells can also contain genes found in the native form of the cell wherein the genes are modified and re-introduced into the cell

by artificial means. The term also encompasses cells that contain a nucleic acid endogenous to the cell that has been modified without removing the nucleic acid from the cell; such modifications include those obtained by gene replacement, site-specific mutation, and related techniques. A "recombinant protein" is one which has been produced by a recombinant cell.

5 [0064] A "fusion protein" refers to a protein comprising amino acid sequences that are in addition to, in place of, less than, and/or different from the amino acid sequences encoding the original or native full-length protein or subsequences thereof.

[0065] Components of fusion proteins include "accessory enzymes" and/or "purification tags." An "accessory enzyme" as referred to herein, is an enzyme that is involved in catalyzing a reaction that, for example, forms a substrate for a glycosyltransferase. An  
10 accessory enzyme can, for example, catalyze the formation of a nucleotide sugar that is used as a donor moiety by a glycosyltransferase. An accessory enzyme can also be one that is used in the generation of a nucleotide triphosphate required for formation of a nucleotide sugar, or in the generation of the sugar which is incorporated into the nucleotide sugar. The

15 recombinant fusion protein of the invention can be constructed and expressed as a fusion protein with a molecular "purification tag" at one end, which facilitates purification of the protein. Such tags can also be used for immobilization of a protein of interest during the glycosylation reaction. Suitable tags include "epitope tags," which are a protein sequence that is specifically recognized by an antibody. Epitope tags are generally incorporated into  
20 fusion proteins to enable the use of a readily available antibody to unambiguously detect or isolate the fusion protein. A "FLAG tag" is a commonly used epitope tag, specifically recognized by a monoclonal anti-FLAG antibody, consisting of the sequence AspTyrLysAspAspAsp AspLys or a substantially identical variant thereof. Other suitable tags are known to those of skill in the art, and include, for example, an affinity tag such as a  
25 hexahistidine peptide, which will bind to metal ions such as nickel or cobalt ions. Proteins comprising purification tags can be purified using a binding partner that binds the purification tag, *e.g.*, antibodies to the purification tag, nickel or cobalt ions or resins, and amylose, maltose, or a cyclodextrin. Purification tags also include maltose binding domains and starch binding domains. Purification of maltose binding domain proteins is known to those of skill  
30 in the art. Starch binding domains are described in WO 99/15636, herein incorporated by reference. Affinity purification of a fusion protein comprising a starch binding domain using a betacylodextrin (BCD)-derivatized resin is described in USSN 60/468,374, filed May 5, 2003, herein incorporated by reference in its entirety.

[0066] The term “functional domain” with reference to glycosyltransferases, refers to a domain of the glycosyltransferase that confers or modulates an activity of the enzyme, *e.g.*, acceptor substrate specificity, catalytic activity, binding affinity, localization within the Golgi apparatus, anchoring to a cell membrane, or other biological or biochemical activity.

5 Examples of functional domains of glycosyltransferases include, but are not limited to, the catalytic domain, stem region, and signal-anchor domain.

[0067] The terms “expression level” or “level of expression” with reference to a protein refers to the amount of a protein produced by a cell. The amount of protein produced by a cell can be measured by the assays and activity units described herein or known to one skilled  
10 in the art. One skilled in the art would know how to measure and describe the amount of protein produced by a cell using a variety of assays and units, respectively. Thus, the quantitation and quantitative description of the level of expression of a protein, *e.g.*, a glycosyltransferase, is not limited to the assays used to measure the activity or the units used to describe the activity, respectively. The amount of protein produced by a cell can be  
15 determined by standard known assays, for example, the protein assay by Bradford (1976), the bicinchoninic acid protein assay kit from Pierce (Rockford, Illinois), or as described in U.S. Patent No. 5,641,668.

[0068] The term “enzymatic activity” refers to an activity of an enzyme and may be measured by the assays and units described herein or known to one skilled in the art.

20 Examples of an activity of a glycosyltransferase include, but are not limited to, those associated with the functional domains of the enzyme, *e.g.*, acceptor substrate specificity, catalytic activity, binding affinity, localization within the Golgi apparatus, anchoring to a cell membrane, or other biological or biochemical activity.

[0069] A “stem region” with reference to glycosyltransferases refers to a protein domain, or  
25 a subsequence thereof, which in the native glycosyltransferases is located adjacent to the trans-membrane domain, and has been reported to function as a retention signal to maintain the glycosyltransferase in the Golgi apparatus and as a site of proteolytic cleavage.

Exemplary stem regions include, but is not limited to, the stem region of fucosyltransferase VI, amino acid residues 40-54; the stem region of mammalian GnT1, amino acid residues  
30 from about 36 to about 103 (see, *e.g.*, the human enzyme); the stem region of mammalian GalT1, amino acid residues from about 71 to about 129 (see *e.g.*, the bovine enzyme); and the

stem region of mammalian ST3GalIII, amino acid residues from about 29 to about 84 (see, *e.g.*, the rat enzyme).

**[0070]** A “catalytic domain” refers to a protein domain, or a subsequence thereof, that catalyzes an enzymatic reaction performed by the enzyme. For example, a catalytic domain of a sialyltransferase will include a subsequence of the sialyltransferase sufficient to transfer a sialic acid residue from a donor to an acceptor saccharide. A catalytic domain can include an entire enzyme, a subsequence thereof, or can include additional amino acid sequences that are not attached to the enzyme, or a subsequence thereof, as found in nature. An exemplary catalytic region is, but is not limited to, the catalytic domain of fucosyltransferase VII, amino acid residues 39-342; the catalytic domain of mammalian GnT1, amino acid residues from about 104 to about 445 (see, *e.g.*, the human enzyme); the catalytic domain of mammalian GalT1, amino acid residues from about 130 to about 402 (see *e.g.*, the bovine enzyme); and the catalytic domain of mammalian ST3GalIII, amino acid residues from about 85 to about 374 (see, *e.g.*, the rat enzyme).

**[0071]** A “subsequence” refers to a sequence of nucleic acids or amino acids that comprise a part of a longer sequence of nucleic acids or amino acids (*e.g.*, protein) respectively.

**[0072]** The term “nucleic acid” refers to a deoxyribonucleotide or ribonucleotide polymer in either single-or double-stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

**[0073]** A “recombinant expression cassette” or simply an “expression cassette” is a nucleic acid construct, generated recombinantly or synthetically, with nucleic acid elements that are capable of affecting expression of a structural gene in hosts compatible with such sequences. Expression cassettes include at least promoters and optionally, transcription termination signals. Typically, the recombinant expression cassette includes a nucleic acid to be transcribed (*e.g.*, a nucleic acid encoding a desired polypeptide), and a promoter. Additional factors necessary or helpful in effecting expression may also be used as described herein. For example, an expression cassette can also include nucleotide sequences that encode a signal sequence that directs secretion of an expressed protein from the host cell. Transcription termination signals, enhancers, and other nucleic acid sequences that influence gene expression, can also be included in an expression cassette.

[0074] A “heterologous sequence” or a “heterologous nucleic acid”, as used herein, is one that originates from a source foreign to the particular host cell, or, if from the same source, is modified from its original form. Thus, a heterologous glycoprotein gene in a eukaryotic host cell includes a glycoprotein-encoding gene that is endogenous to the particular host cell that has been modified. Modification of the heterologous sequence may occur, *e.g.*, by treating the DNA with a restriction enzyme to generate a DNA fragment that is capable of being operably linked to the promoter. Techniques such as site-directed mutagenesis are also useful for modifying a heterologous sequence.

[0075] The term “isolated” refers to material that is substantially or essentially free from components which interfere with the activity of an enzyme. For a saccharide, protein, or nucleic acid of the invention, the term “isolated” refers to material that is substantially or essentially free from components which normally accompany the material as found in its native state. Typically, an isolated saccharide, protein, or nucleic acid of the invention is at least about 80% pure, usually at least about 90%, and preferably at least about 95% pure as measured by band intensity on a silver stained gel or other method for determining purity. Purity or homogeneity can be indicated by a number of means well known in the art. For example, a protein or nucleic acid in a sample can be resolved by polyacrylamide gel electrophoresis, and then the protein or nucleic acid can be visualized by staining. For certain purposes high resolution of the protein or nucleic acid may be desirable and HPLC or a similar means for purification, for example, may be utilized.

[0076] The term “operably linked” refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.

[0077] The terms “identical” or percent “identity,” in the context of two or more nucleic acids or protein sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.

[0078] The phrase “substantially identical,” in the context of two nucleic acids or proteins, refers to two or more sequences or subsequences that have at least greater than about 60%

nucleic acid or amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues. In a most preferred embodiment, the sequences are substantially identical over the entire length of the coding regions.

[0079] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0080] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (*see generally, Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)).

[0081] Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.* (1990) *J. Mol. Biol.* 215: 403-410 and Altschuel *et al.* (1977) *Nucleic Acids Res.* 25: 3389-3402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information ([www.ncbi.nlm.nih.gov/](http://www.ncbi.nlm.nih.gov/)). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the

same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al, supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

[0082] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.,* Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0083] A further indication that two nucleic acid sequences or proteins are substantially identical is that the protein encoded by the first nucleic acid is immunologically cross reactive with the protein encoded by the second nucleic acid, as described below. Thus, a protein is typically substantially identical to a second protein, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.

[0084] The phrase “hybridizing specifically to” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (*e.g.*, total cellular) DNA or RNA.

[0085] The term “stringent conditions” refers to conditions under which a probe will

5 hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 15°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH,  
10 and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium).

Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to  
15 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is typically at least two times background, preferably 10 times background hybridization. Exemplary stringent

20 hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42° C, or, 5x SSC, 1% SDS, incubating at 65° C, with wash in 0.2x SSC, and 0.1% SDS at 65° C. For PCR, a temperature of about 36° C is typical for low stringency amplification, although annealing temperatures may vary between about 32-48° C depending on primer length. For high stringency PCR amplification, a temperature of about 62° C is  
25 typical, although high stringency annealing temperatures can range from about 50° C to about 65° C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90-95° C for 30-120 sec, an annealing phase lasting 30-120 sec, and an extension phase of about 72° C for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are available,  
30 *e.g.*, in Innis, et al. (1990) *PCR Protocols: A Guide to Methods and Applications* Academic Press, N.Y.



[0086] The phrases “specifically binds to a protein” or “specifically immunoreactive with”, when referring to an antibody refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind preferentially to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

[0087] “Conservatively modified variations” of a particular polynucleotide sequence refers to those polynucleotides that encode identical or essentially identical amino acid sequences, or where the polynucleotide does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons CGU, CGC, CGA, CCG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded protein. Such nucleic acid variations are “silent variations,” which are one species of “conservatively modified variations.” Every polynucleotide sequence described herein which encodes a protein also describes every possible silent variation, except where otherwise noted. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and UGG which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule by standard techniques. Accordingly, each “silent variation” of a nucleic acid which encodes a protein is implicit in each described sequence.

[0088] Furthermore, one of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 1%) in an encoded sequence are “conservatively modified variations” where the alterations result in the substitution of an

amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

[0089] One of skill will appreciate that many conservative variations of proteins, *e.g.*, glycosyltransferases, and nucleic acid which encode proteins yield essentially identical products. For example, due to the degeneracy of the genetic code, “silent substitutions” (*i.e.*, substitutions of a nucleic acid sequence which do not result in an alteration in an encoded protein) are an implied feature of every nucleic acid sequence which encodes an amino acid. As described herein, sequences are preferably optimized for expression in a particular host cell used to produce the chimeric glycosyltransferases (*e.g.*, yeast, human, and the like). Similarly, “conservative amino acid substitutions,” in one or a few amino acids in an amino acid sequence are substituted with different amino acids with highly similar properties (*see*, the definitions section, *supra*), are also readily identified as being highly similar to a particular amino acid sequence, or to a particular nucleic acid sequence which encodes an amino acid. Such conservatively substituted variations of any particular sequence are a feature of the present invention. *See also*, Creighton (1984) *Proteins*, W.H. Freeman and Company. In addition, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence are also “conservatively modified variations”.

[0090] The practice of this invention can involve the construction of recombinant nucleic acids and the expression of genes in host cells, preferably bacterial host cells. Molecular cloning techniques to achieve these ends are known in the art. A wide variety of cloning and *in vitro* amplification methods suitable for the construction of recombinant nucleic acids such as expression vectors are well known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* volume 152 Academic Press, Inc., San Diego, CA (Berger); and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1999 Supplement) (Ausubel). Suitable host cells for expression of the recombinant polypeptides are known to those of skill in the art, and include, for example, prokaryotic cells, such as *E. coli*, and eukaryotic cells including insect, mammalian and fungal cells (*e.g.*, *Aspergillus niger*)

[0091] Examples of protocols sufficient to direct persons of skill through *in vitro* amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q $\beta$ -replicase amplification and other RNA polymerase mediated techniques are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.* (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.* eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3: 81-94; (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87: 1874; Lomell *et al.* (1989) *J. Clin. Chem.* 35: 1826; Landegren *et al.* (1988) *Science* 241: 1077-1080; Van Brunt (1990) *Biotechnology* 8: 291-294; Wu and Wallace (1989) *Gene* 4: 560; and Barringer *et al.* (1990) *Gene* 89: 117. Improved methods of cloning *in vitro* amplified nucleic acids are described in Wallace *et al.*, U.S. Pat. No. 5,426,039.

## DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

[0092] The present invention provides conditions for refolding eukaryotic glycosyltransferases that are expressed as insoluble proteins in bacterial inclusion bodies. Refolding buffers comprising redox couples are used to enhance refolding of insoluble eukaryotic glycosyltransferases. For some insoluble eukaryotic glycosyltransferases, refolding can be enhanced by site directed mutagenesis to remove unpaired cysteines. The invention also provides methods to refold more than one glycosyltransferase in a single vessel, thereby enhancing refolding of the proteins and increasing efficiency of protein production. The refolded eukaryotic glycosyltransferases can be used to produce or to remodel polysaccharides, oligosaccharides, glycolipids, and glycoproteins. The refolded eukaryotic glycosyltransferases can also be used to glycoPEGylate glycoproteins as described in PCT/US02/32263, which is herein incorporated by reference for all purposes.

### II. Refolding insoluble glycosyltransferases

[0093] Many recombinant proteins expressed in bacteria are expressed as insoluble aggregates in bacterial inclusion bodies. Inclusion bodies are protein deposits found in both the cytoplasmic and periplasmic space of bacteria. (See, e.g., Clark, *Cur. Op. Biotech.* 12:202-207 (2001)). Eukaryotic glycosyltransferases are frequently expressed in bacterial inclusion bodies. Some eukaryotic glycosyltransferases are soluble in bacteria, *i.e.*, not produced in inclusion bodies, when only the catalytic domain of the protein is expressed. However, many eukaryotic glycosyltransferases are expressed in bacterial inclusion bodies,

even if only the catalytic domain is expressed, and methods for refolding these proteins to produce active glycosyltransferases are provided herein.

*A. Conditions for refolding active glycosyltransferases*

[0094] To produce active eukaryotic glycosyltransferases from bacterial cells, eukaryotic glycosyltransferases are expressed in bacterial inclusion bodies, the bacteria are harvested, disrupted and the inclusion bodies are isolated and washed. The proteins within the inclusion bodies are then solubilized. Solubilization can be performed using denaturants, *e.g.*, guanidinium chloride or urea; extremes of pH; or detergents.

[0095] After solubilization, denaturants are removed from the glycosyltransferase mixture. Denaturant removal can be done by a variety of methods, including dilution into a refolding buffer or buffer exchange methods. Buffer exchange methods include dialysis, diafiltration, gel filtration, and immobilization of the protein onto a solid support. (*See, e.g., Clark, Cur. Op. Biotech. 12:202-207 (2001)*). Any of the above methods can be combined to remove denaturants.

[0096] Disulfide bond formation in the eukaryotic glycosyltransferase is promoted by addition of a refolding buffer comprising a redox couple. Redox couples include reduced and oxidized glutathione (GSH/GSSG), cysteine/cystine, cysteamine/cystamine, DTT/GSSG, and DTE/GSSG. (*See, e.g., Clark, Cur. Op. Biotech. 12:202-207 (2001)*).

[0097] Refolding can be performed in buffers at pH's ranging from, for example, 6.0 to 10.0. Refolding buffers can include other additives to enhance refolding, *e.g.*, L-arginine (0.4-1M); PEG; low concentrations of denaturants, such as urea (1-2M) and guanidinium chloride (0.5-1.5 M); and detergents (*e.g.*, Chaps, SDS, CTAB, lauryl maltoside, and Triton X-100).

[0098] A catalytic domain of a eukaryotic glycosyltransferases can be expressed in bacterial inclusion bodies and then refolded using the above methods. Eukaryotic glycosyltransferases can be fused to purification tags and expressed in bacterial inclusion bodies and then refolded using the above methods. Purification tags include, *e.g.*, a maltose binding protein (MBP) tag, a polyhistidine tag, a glutathione S transferase (GST), a starch binding protein (SBP), a FLAG epitope, and a myc epitope. Refolded glycosyltransferases can be further purified using a binding partner that binds to the purification tag. In a preferred embodiment, an MBP tag is fused to the eukaryotic glycosyltransferase to enhance refolding.

[0099] Those of skill will recognize that a protein has been refolded correctly when the refolded protein has detectable biological activity. For a glycosyltransferase biological activity is the ability to catalyze transfer of a donor substrate to an acceptor substrate, *e.g.*, a refolded ST3GalIII is able to transfer sialic acid to an acceptor substrate. Biological activity includes *e.g.*, specific activities of at least 1, 2, 5, 7, or 10 units of activity. Unit is defined as follows: one activity unit catalyzes the formation of 1  $\mu\text{mol}$  of product per minute at a given temperature (*e.g.*, at 37°C) and pH value (*e.g.*, at pH 7.5). Thus, 10 units of an enzyme is a catalytic amount of that enzyme where 10  $\mu\text{mol}$  of substrate are converted to 10  $\mu\text{mol}$  of product in one minute at a temperature of, *e.g.*, 37 °C and a pH value of, *e.g.*, 7.5.

[0100] In one embodiment, rat liver *N*-acetyllactosaminide  $\alpha$ -2,3-sialyltransferase (ST3GalIII) is expressed in bacterial inclusion bodies, solubilized, and refolded in a buffer comprising a redox couple, *e.g.*, GSH/GSSG or cystamine/cysteine.

*B. Site directed mutagenesis of glycosyltransferases to enhance refolding*

[0101] As refolding occurs, cysteine residues in a denatured protein form disulfide bonds that help to reproduce the structure of the active protein. Incorrect pairing of cysteine residues can lead to protein misfolding. Proteins with unpaired cysteine residues are susceptible to misfolding because a normally unpaired cysteine can form a disulfide bond with normally paired cysteine making correct cysteine pairing and protein refolding impossible. Thus, one method to enhance refolding of a particular glycosyltransferase is to identify unpaired cysteine residues and remove them.

[0102] Unpaired cysteine residues can be identified by determining the structure of the glycosyltransferase of interest. Protein structure can be determined based on actual data for the glycosyltransferase of interest, *e.g.*, circular dichroism, NMR, and X-ray crystallography. Protein structure can also be determined using computer modeling. Computer modeling is a technique that can be used to model related structures based on known three-dimensional structures of homologous molecules. Standard software is commercially available. (*See e.g.*, [www.accelrys.com](http://www.accelrys.com) for the multitude of software available to do computer modeling.) Once an unpaired cysteine residue is identified, the DNA encoding the glycosyltransferase of interest can be mutated using standard molecular biology techniques to remove the unpaired cysteine, by deletion or by substitution with another amino acid residue. Computer modeling is used again to select an amino acid of appropriate size, shape, and charge for substitution. Unpaired cysteines can also be determined by peptide mapping. Once the glycosyltransferase

of interest is mutated, the protein is expressed in bacterial inclusion bodies and refolding ability is determined. A correctly refolded glycosyltransferase will have biological activity.

[0103] Human N-acetylglucosaminyltransferase I (GnTI, accession number NP\_002397) is an example of a glycosyltransferase that exhibited enhanced refolding after mutagenesis of an unpaired cysteine. (See, e.g., Example 2, below.) Human GnTI is closely related to a number of eukaryotic GnTI proteins, e.g., Chinese hamster, accession number AAK61868; rabbit accession number AAA31493; rat accession number NP\_110488; golden hamster, accession number AAD04130; mouse, accession number P27808; zebrafish, accession number AAH58297; *Xenopus*, accession number CAC51119; *Drosophila*, accession number NP\_525117; *Anopheles*, accession number XP\_315359; *C. elegans*, accession number NP\_497719; *Physcomitrella patens*, accession number CAD22107; *Solanum tuberosum*, accession number CAC80697; *Nicotiana tabacum*, accession number CAC80702; *Oryza sativa*, accession number CAD30022; *Nicotiana benthamiana*, accession number CAC82507; and *Arabidopsis thaliana*, accession number NP\_195537.

[0104] The structure of the rabbit N-acetylglucosaminyltransferase I (GnTI) protein had been determined and showed that CYS123 was unpaired. (Amino acid residue numbers refer to the full length protein sequence even when a GnTI protein has been truncated.) Computer modeling based on the rabbit GnTI was used to determine the structure of the human GnTI protein. An alignment is shown in Figure 6. In the human GnTI protein, CYS121 was unpaired. Substitutions for CYS121 were made in human GnTI. A CYS121SER mutant and a CYS121ALA mutant were active. In contrast, a CYS121THR mutant had no detectable activity and a CYS121ASP mutant had low activity. A double mutant, ARG120ALA, CYS121HIS, was constructed based on the predicted structure of the *C. elegans* GnTI protein, and had activity.

[0105] The amino acid sequences of the eukaryotic GnTI proteins listed above can be used to determine protein structure based on computer modeling and the conserved function of CYS123 from rabbit and CYS121 from human. Based on that analysis, residue 123 is an unpaired cysteine in the following proteins: Chinese hamster GnTI, the rabbit GnTI, the rat GnTI, the golden hamster GnTI, and the mouse GnTI. Thus, CYS123 can be mutated in each of the GnTI enzymes to serine, alanine, or arginine to produce an active protein with enhanced refolding activity. The following double mutant in the above proteins, ARG122ALA, CYS123HIS, will also exhibit enhanced refolding.

### C. One pot refolding of glycosyltransferases

[0106] These embodiments of the invention are based on the surprising observation that multiple eukaryotic glycosyltransferases expressed in bacterial inclusion bodies can be refolded in a single vessel, *i.e.*, a one pot method. Using this method at least two glycosyltransferases can be refolded together resulting in savings of time and materials. Refolding conditions are described above. The refolding conditions are optimized for the mixture of glycosyltransferases, thus, conditions may not be optimal for any particular enzyme in the mixture. However, because refolding is optimized for the combination of glycosyltransferases, each of the refolded glycosyltransferases in the end product has detectable biological activity. Biological activity refers to enzymatic activity of the refolded enzymes and can be expressed as specific activity. Biological activity includes *e.g.*, specific activities of at least 0.1, 0.5, 1, 2, 5, 7, or 10 units of activity. Unit is defined as follows: one activity unit catalyzes the formation of 1  $\mu$ mol of product per minute at a given temperature (*e.g.*, at 37°C) and pH value (*e.g.*, at pH 7.5). Thus, 10 units of an enzyme is a catalytic amount of that enzyme where 10  $\mu$ mol of substrate are converted to 10  $\mu$ mol of product in one minute at a temperature of, *e.g.*, 37 °C and a pH value of, *e.g.*, 7.5. The reaction mixture comprising refolded glycosyltransferases can then be used *e.g.*, to synthesize oligosaccharides, to synthesize glycolipids, to remodel glycoproteins, and to glycoPEGylate glycoproteins.

[0107] In some embodiments, the glycosyltransferases can be solubilized individually from inclusion bodies and then combined under conditions appropriate for refolding. In other embodiments, inclusion bodies containing glycosyltransferases are combined, solubilized, and then refolded under appropriate conditions.

[0108] Refolding buffers typically include a redox couple. Refolding can be performed at pH's ranging from, for example, 6.0 to 10.0. Refolding buffers can include other additives to enhance refolding, *e.g.*, L-arginine (0.4-1M); PEG; low concentrations of denaturants, such as urea (1-2M) and guanidinium chloride (0.5-1.5 M); and detergents (*e.g.*, Chaps, SDS, CTAB, and Triton X-100).

[0109] In some embodiments, refolding is performed in a stationary vessel, *i.e.*, without mixing, stirring, shaking or otherwise moving the reaction mixture.

[0110] The combination of refolded enzymes can include enzymes to construct a particular oligosaccharide structure. Those of skill will be able to identify appropriate glycosyltransferases for inclusion in the mixture once a desired end product is identified.

[0111] The reaction mixtures of refolded enzymes can include glycosyltransferases that have been mutated to enhance refolding, *e.g.*, the GnTI enzymes described above.

[0112] In a preferred embodiment, enzymes that perform N-linked glycosylation steps are refolded together in a single vessel. For example, *N*-acetylglucosaminyltransferase I (GnTI),  $\beta$ -1,4 galactosyltransferase I (Gal TI), and *N*-acetyllactosaminide  $\alpha$ -2,3-sialyltransferase (ST3GalIII) can be expressed in bacterial inclusion bodies, solubilized, and refolded together in a single vessel. The end product exhibited activity of all three proteins, indicating they were all correctly refolded. Refolding also occurred when GnTI and Gal TI were refolded together without ST3GalIII. The experiments are described in detail in Example 3.

### III. Glycosyltransferases

[0113] The glycosyltransferases of use in practicing the present invention are eukaryotic glycosyltransferases. Examples of such glycosyltransferases include those described in Staudacher, E. (1996) *Trends in Glycoscience and Glycotechnology*, **8**: 391-408, <http://afmb.cnrs-mrs.fr/~pedro/CAZY/gtf.html> and [http://www.vei.co.uk/TGN/gt\\_guide.htm](http://www.vei.co.uk/TGN/gt_guide.htm), but are not limited thereto.

#### Eukaryotic glycosyltransferases

[0114] Some eukaryotic glycosyltransferases have topological domains at their amino terminus that are not required for catalytic activity (*see*, US Patent No. 5, 032,519). Of the glycosyltransferases characterized to date, the “cytoplasmic domain,” is most commonly between about 1 and about 10 amino acids in length, and is the most amino-terminal domain; the adjacent domain, termed the “signal-anchor domain,” is generally between about 10-26 amino acids in length; adjacent to the signal-anchor domain is a “stem region,” which is generally between about 20 and about 60 amino acids in length, and known to function as a retention signal to maintain the glycosyltransferase in the Golgi apparatus; and at the carboxyl side of the stem region is the catalytic domain.

[0115] Many mammalian glycosyltransferases have been cloned and expressed and the recombinant proteins have been characterized in terms of donor and acceptor substrate specificity and they have also been investigated through site directed mutagenesis in attempts to define residues or domains involved in either donor or acceptor substrate specificity (Aoki



*et al.* (1990) *EMBO. J.* 9: 3171-3178; Harduin-Lepers *et al.* (1995) *Glycobiology* 5(8): 741-758; Natsuka and Lowe (1994) *Current Opinion in Structural Biology* 4: 683-691; Zu *et al.* (1995) *Biochem. Biophys. Res. Comm.* 206(1): 362-369; Seto *et al.* (1995) *Eur. J. Biochem.* 234: 323-328; Seto *et al.* (1997) *J. Biol. Chem.* 272: 14133-14138).

- 5    **[0116]** In one group of embodiments, a functional domain of the recombinant glycosyltransferase proteins of the present invention is obtained from a known sialyltransferase. Examples of sialyltransferases that are suitable for use in the present invention include, but are not limited to, ST3GalIII, ST3Gal IV, ST3Gal I, ST6Gal I, ST3Gal V, ST6Gal II, ST6GalNAc I, ST6GalNAc II, and ST6GalNAc III (the sialyltransferase
- 10    nomenclature used herein is as described in Tsuji *et al.* (1996) *Glycobiology* 6: v-xiv). An exemplary  $\alpha$ 2,3-sialyltransferase (EC 2.4.99.6) transfers sialic acid to the non-reducing terminal Gal of a Gal $\beta$ 1 $\rightarrow$ 4GlcNAc disaccharide or glycoside. *See*, Van den Eijnden *et al.*, *J. Biol. Chem.*, 256:3159 (1981), Weinstein *et al.*, *J. Biol. Chem.*, 257:13845 (1982) and Wen *et al.*, *J. Biol. Chem.*, 267:21011 (1992). Another exemplary  $\alpha$ 2,3-sialyltransferase (EC
- 15    2.4.99.4) transfers sialic acid to the non-reducing terminal Gal of a Gal $\beta$ 1 $\rightarrow$ 3GalNAc disaccharide or glycoside. *See*, Rearick *et al.*, *J. Biol. Chem.*, 254: 4444 (1979) and Gillespie *et al.*, *J. Biol. Chem.*, 267:21004 (1992). Further exemplary enzymes include Gal- $\beta$ -1,4-GlcNAc  $\alpha$ -2,6 sialyltransferase (*See*, Kurosawa *et al.* *Eur. J. Biochem.* 219: 375-381 (1994)). Sialyltransferase nomenclature is described in Tsuji, S. *et al.* (1996) *Glycobiology* 6:v-vii.
- 20    **[0117]** An example of a sialyltransferase that is useful in the claimed methods is ST3GalIII, which is also referred to as  $\alpha$ (2,3)sialyltransferase (EC 2.4.99.6). This enzyme catalyzes the transfer of sialic acid to the Gal of a Gal $\beta$ 1,3GlcNAc, Gal $\beta$ 1,3GalNAc or Gal $\beta$ 1,4GlcNAc glycoside (*see, e.g.*, Wen *et al.* (1992) *J. Biol. Chem.* 267: 21011; Van den Eijnden *et al.* (1991) *J. Biol. Chem.* 256: 3159). The sialic acid is linked to a Gal with the formation of an
- 25     $\alpha$ -linkage between the two saccharides. Bonding (linkage) between the saccharides is between the 2-position of NeuAc and the 3-position of Gal. This particular enzyme can be isolated from rat liver (Weinstein *et al.* (1982) *J. Biol. Chem.* 257: 13845); the human cDNA (Sasaki *et al.* (1993) *J. Biol. Chem.* 268: 22782-22787; Kitagawa & Paulson (1994) *J. Biol. Chem.* 269: 1394-1401) and genomic (Kitagawa *et al.* (1996) *J. Biol. Chem.* 271: 931-938)
- 30    DNA sequences are known, facilitating production of this enzyme by recombinant expression. In a preferred embodiment, the claimed sialylation methods use a rat ST3GalIII.

[0118] In another group of embodiments, a functional domain of the recombinant glycosyltransferase proteins of the present inventions is obtained from a fucosyltransferase. A number of fucosyltransferases are known to those of skill in the art. Briefly, fucosyltransferases include any of those enzymes which transfer L-fucose from GDP-fucose to a hydroxy position of an acceptor sugar. In some embodiments, for example, the acceptor sugar is a GlcNAc in a Gal $\beta$ (1 $\rightarrow$ 4)GlcNAc group in an oligosaccharide glycoside. Suitable fucosyltransferases for this reaction include the known Gal $\beta$  (1 $\rightarrow$ 3,4)GlcNAc  $\alpha$ (1 $\rightarrow$ 3,4)fucosyltransferase (FTIII, E.C. No. 2.4.1.65) which is obtained from human milk (see, Palcic, *et al.*, *Carbohydrate Res.* 190:1-11 (1989); Pricels, *et al.*, *J. Biol. Chem.* 256: 10456-10463 (1981); and Nunez, *et al.*, *Can. J. Chem.* 59: 2086-2095 (1981)) and the Gal $\beta$ (1 $\rightarrow$ 4)GlcNAc  $\alpha$ (1 $\rightarrow$ 3)fucosyltransferases (FTIV, FTV, and FTVI, E.C. No. 2.4.1.65) and NeuAc $\alpha$ (2,3) $\beta$ Gal(1 $\rightarrow$ 4) $\beta$ GlcNAc  $\alpha$ (1 $\rightarrow$ 3)fucosyltransferases (FTVII) which are found in human serum. Also, available is the  $\alpha$ 1,3 fucosyltransferase IX (nucleotide sequences of human and mouse FTIX) as described in Kaneko *et al.* (1999) *FEBS Lett.* 452: 237-242. In addition, a recombinant form of Gal $\beta$  (1 $\rightarrow$ 3,4)GlcNAc  $\alpha$ (1 $\rightarrow$ 3,4)fucosyltransferase is available (see, Dumas, *et al.*, *Bioorg. Med. Letters* 1:425-428 (1991) and Kukowska-Latallo, *et al.*, *Genes and Development* 4:1288-1303 (1990)). Other exemplary fucosyltransferases include  $\alpha$ 1,2 fucosyltransferase (E.C. No. 2.4.1.69). Enzymatic fucosylation can be carried out by the methods described in Mollicone, *et al.*, *Eur. J. Biochem.* 191:169-176 (1990) or U.S. Patent No. 5,374,655.

[0119] In another group of embodiments, a functional domain of the recombinant glycosyltransferase proteins of the present inventions is obtained from known galactosyltransferases. Exemplary galactosyltransferases include  $\beta$ -1,4 galactosyltransferase I,  $\alpha$ 1,3- galactosyltransferases (E.C. No. 2.4.1.151, see, e.g., Dabkowski *et al.*, *Transplant Proc.* 25:2921 (1993) and Yamamoto *et al.* *Nature* 345:229-233 (1990), bovine (GenBank j04989, Joziase *et al.* (1989) *J. Biol. Chem.* 264:14290-14297), murine (GenBank m26925; Larsen *et al.* (1989) *Proc. Nat'l. Acad. Sci. USA* 86:8227-8231), porcine (GenBank L36152; Strahan *et al.* (1995) *Immunogenetics* 41:101-105)). Another suitable  $\alpha$ 1,3- galactosyltransferase is that which is involved in synthesis of the blood group B antigen (EC 2.4.1.37, Yamamoto *et al.* (1990) *J. Biol. Chem.* 265:1146-1151 (human)). Also suitable for use in the fusion proteins of the invention are  $\alpha$ 1,4-galactosyltransferases, which include, for example, EC 2.4.1.90 (LacNAc synthetase) and EC 2.4.1.22 (lactose synthetase) (bovine

(D'Agostaro et al (1989) *Eur. J. Biochem.* 183:211-217), human (Masri *et al.* (1988) *Biochem. Biophys. Res. Commun.* 157:657-663), murine (Nakazawa et al (1988) *J. Biochem.* 104:165-168), as well as E.C. 2.4.1.38 and the ceramide galactosyltransferase (EC 2.4.1.45, Stahl *et al.* (1994) *J. Neurosci. Res.* 38:234-242). Other suitable galactosyltransferases include, for example,  $\alpha$ 1,2-galactosyltransferases (from *e.g.*, *Schizosaccharomyces pombe*, Chapell *et al* (1994) *Mol. Biol. Cell* 5:519-528).

[0120] Other glycosyltransferases that are useful in the recombinant fusion proteins of the present invention have been described in detail, as for the sialyltransferases, galactosyltransferases, and fucosyltransferases. In particular, the glycosyltransferase can also be, for instance, a glucosyltransferase, *e.g.*, Alg8 (Stagljev *et al.*, *Proc. Natl. Acad. Sci. USA* 91:5977 (1994)) or Alg5 (Heesen *et al.* *Eur. J. Biochem.* 224:71 (1994)), N-acetylgalactosaminyltransferases such as, for example,  $\beta$ (1,3)-N-acetylgalactosaminyltransferase,  $\beta$ (1,4)-N-acetylgalactosaminyltransferases (US Patent No. 5,691,180, Nagata *et al.* *J. Biol. Chem.* 267:12082-12089 (1992), and Smith *et al.* *J. Biol Chem.* 269:15162 (1994)) and protein N-acetylgalactosaminyltransferase (Homa *et al.* *J. Biol Chem.* 268:12609 (1993)). Suitable N-acetylglucosaminyltransferases include GnTI (2.4.1.101, Hull *et al.*, *BBRC* 176:608 (1991)), GnTII, and GnTIII (Ihara *et al.* *J. Biochem.* 113:692 (1993)), GnTV (Shoreiban *et al.* *J. Biol. Chem.* 268: 15381 (1993)), O-linked N-acetylglucosaminyltransferase (Bierhuizen *et al.* *Proc. Natl. Acad. Sci. USA* 89:9326 (1992)), N-acetylglucosamine-1-phosphate transferase (Rajput *et al.* *Biochem J.* 285:985 (1992), and hyaluronan synthase. Also of interest are enzymes involved in proteoglycan synthesis, such as, for example, N-acetylgalactosaminyltransferase I (EC 2.4.1.174), and enzymes involved in chondroitin sulfate synthesis, such as N-acetylgalactosaminyltransferase II (EC 2.4.1.175). Suitable mannosyltransferases include  $\alpha$ (1,2) mannosyltransferase,  $\alpha$ (1,3) mannosyltransferase,  $\beta$ (1,4) mannosyltransferase, Dol-P-Man synthase, OCh1, and Pmt1. Xylosyltransferases include, for example, protein xylosyltransferase (EC 2.4.2.26).

#### IV. Nucleic acids

[0121] Nucleic acids that encode glycosyltransferases, and methods of obtaining such nucleic acids, are known to those of skill in the art. Suitable nucleic acids (*e.g.*, cDNA, genomic, or subsequences (probes)) can be cloned, or amplified by *in vitro* methods such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), or the self-sustained sequence replication system (SSR). A wide

variety of cloning and *in vitro* amplification methodologies are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook *et al.*); *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel); Cashion *et al.*, U.S. patent number 5,017,478; and Carr, European Patent No. 0,246,864.

[0122] A DNA that encodes a glycosyltransferase, or a subsequences thereof, can be prepared by any suitable method described above, including, for example, cloning and restriction of appropriate sequences with restriction enzymes. In one preferred embodiment, nucleic acids encoding glycosyltransferases are isolated by routine cloning methods. A nucleotide sequence of a glycosyltransferase as provided in, for example, GenBank or other sequence database (see above) can be used to provide probes that specifically hybridize to a glycosyltransferase gene in a genomic DNA sample, or to an mRNA, encoding a glucosyltransferase, in a total RNA sample (*e.g.*, in a Southern or Northern blot). Once the target nucleic acid encoding a glycosyltransferase is identified, it can be isolated according to standard methods known to those of skill in the art (*see, e.g.*, Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual, 2nd Ed., Vols. 1-3*, Cold Spring Harbor Laboratory; Berger and Kimmel (1987) *Methods in Enzymology, Vol. 152: Guide to Molecular Cloning Techniques*, San Diego: Academic Press, Inc.; or Ausubel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York). Further, the isolated nucleic acids can be cleaved with restriction enzymes to create nucleic acids encoding the full-length glycosyltransferase, or subsequences thereof, *e.g.*, containing subsequences encoding at least a subsequence of a stem region or catalytic domain of a glycosyltransferase. These restriction enzyme fragments, encoding a glycosyltransferase or subsequences thereof, may then be ligated, for example, to produce a nucleic acid encoding a recombinant glycosyltransferase fusion protein.

[0123] A nucleic acid encoding a glycosyltransferase, or a subsequence thereof, can be characterized by assaying for the expressed product. Assays based on the detection of the physical, chemical, or immunological properties of the expressed protein can be used. For

example, one can identify a cloned glycosyltransferase, including a glycosyltransferase fusion protein, by the ability of a protein encoded by the nucleic acid to catalyze the transfer of a saccharide from a donor substrate to an acceptor substrate. In a preferred method, capillary electrophoresis is employed to detect the reaction products. This highly sensitive assay involves using either saccharide or disaccharide aminophenyl derivatives which are labeled with fluorescein as described in Wakarchuk *et al.* (1996) *J. Biol. Chem.* 271 (45): 28271-276. For example, to assay for a *Neisseria lgtC* enzyme, either FCHASE-AP-Lac or FCHASE-AP-Gal can be used, whereas for the *Neisseria lgtB* enzyme an appropriate reagent is FCHASE-AP-GlcNAc (*Id.*).

[0124] Also, a nucleic acid encoding a glycosyltransferase, or a subsequence thereof, can be chemically synthesized. Suitable methods include the phosphotriester method of Narang *et al.* (1979) *Meth. Enzymol.* 68: 90-99; the phosphodiester method of Brown *et al.* (1979) *Meth. Enzymol.* 68: 109-151; the diethylphosphoramidite method of Beaucage *et al.* (1981) *Tetra. Lett.*, 22: 1859-1862; and the solid support method of U.S. Patent No. 4,458,066.

Chemical synthesis produces a single stranded oligonucleotide. This can be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill recognizes that while chemical synthesis of DNA is often limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of shorter sequences.

[0125] Nucleic acids encoding glycosyltransferases, or subsequences thereof, can be cloned using DNA amplification methods such as polymerase chain reaction (PCR). Thus, for example, the nucleic acid sequence or subsequence is PCR amplified, using a sense primer containing one restriction enzyme site (*e.g.*, *NdeI*) and an antisense primer containing another restriction enzyme site (*e.g.*, *HindIII*). This will produce a nucleic acid encoding the desired glycosyltransferase or subsequence and having terminal restriction enzyme sites. This nucleic acid can then be easily ligated into a vector containing a nucleic acid encoding the second molecule and having the appropriate corresponding restriction enzyme sites. Suitable PCR primers can be determined by one of skill in the art using the sequence information provided in GenBank or other sources. Appropriate restriction enzyme sites can also be added to the nucleic acid encoding the glycosyltransferase protein or protein subsequence by site-directed mutagenesis. The plasmid containing the glycosyltransferase-encoding nucleotide sequence or subsequence is cleaved with the appropriate restriction endonuclease and then ligated into an appropriate vector for amplification and/or expression according to

standard methods. Examples of techniques sufficient to direct persons of skill through *in vitro* amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.*, eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3: 81-94; (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell *et al.* (1989) *J. Clin. Chem.*, 35: 1826; Landegren *et al.*, (1988) *Science* 241: 1077-1080; Van Brunt (1990) *Biotechnology* 8: 291-294; Wu and Wallace (1989) *Gene* 4: 560; and Barringer *et al.* (1990) *Gene* 89: 117.

[0126] Other physical properties of a cloned glycosyltransferase protein, including glycosyltransferase fusion protein, expressed from a particular nucleic acid, can be compared to properties of known glycosyltransferases to provide another method of identifying suitable sequences or domains of the glycosyltransferase that are determinants of acceptor substrate specificity and/or catalytic activity. Alternatively, a putative glycosyltransferase gene or recombinant glycosyltransferase gene can be mutated, and its role as glycosyltransferase, its ability to be refolded, or the role of particular sequences or domains established by detecting a variation in the structure of a carbohydrate normally produced by the unmutated, naturally-occurring, or control glycosyltransferase.

[0127] Functional domains of cloned glycosyltransferases can be identified by using standard methods for mutating or modifying the glycosyltransferases and testing the modified or mutated proteins for activities such as acceptor substrate activity and/or catalytic activity, as described herein. The functional domains of the various glycosyltransferases can be used to construct nucleic acids encoding recombinant glycosyltransferase fusion proteins comprising the functional domains of one or more glycosyltransferases. These fusion proteins can then be tested for the desired acceptor substrate or catalytic activity.

[0128] In an exemplary approach to cloning recombinant glycosyltransferase fusion proteins, the known nucleic acid or amino acid sequences of cloned glycosyltransferases are aligned and compared to determine the amount of sequence identity between various glycosyltransferases. This information can be used to identify and select protein domains that confer or modulate glycosyltransferase activities, *e.g.*, acceptor substrate activity and/or catalytic activity based on the amount of sequence identity between the glycosyltransferases of interest. For example, domains having sequence identity between the glycosyltransferases

of interest, and that are associated with a known activity, can be used to construct recombinant glycosyltransferase fusion proteins containing that domain, and having the activity associated with that domain (e.g., acceptor substrate specificity and/or catalytic activity).

## 5    **V.      Expression of recombinant glycosyltransferases**

[0129] Recombinant eukaryotic glycosyltransferases can be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. The host cells can be mammalian cells, plant cells, or microorganisms, such as, for example, yeast cells, bacterial  
10 cells, or filamentous fungal cells. Examples of suitable host cells include, for example, *Azotobacter sp.* (e.g., *A. vinelandii*), *Pseudomonas sp.*, *Rhizobium sp.*, *Erwinia sp.*, *Escherichia sp.* (e.g., *E. coli*), *Bacillus*, *Pseudomonas*, *Proteus*, *Salmonella*, *Serratia*, *Shigella*, *Rhizobia*, *Vitreoscilla*, *Paracoccus* and *Klebsiella sp.*, among many others. The cells can be of any of several genera, including *Saccharomyces* (e.g., *S. cerevisiae*), *Candida*  
15 (e.g., *C. utilis*, *C. parapsilosis*, *C. krusei*, *C. versatilis*, *C. lipolytica*, *C. zeylanoides*, *C. guilliermondii*, *C. albicans*, and *C. humicola*), *Pichia* (e.g., *P. farinosa* and *P. ohmeri*), *Torulopsis* (e.g., *T. candida*, *T. sphaerica*, *T. xylinus*, *T. famata*, and *T. versatilis*), *Debaryomyces* (e.g., *D. subglobosus*, *D. cantarellii*, *D. globosus*, *D. hansenii*, and *D. japonicus*), *Zygosaccharomyces* (e.g., *Z. rouxii* and *Z. bailii*), *Kluyveromyces* (e.g., *K. marxianus*), *Hansenula* (e.g., *H. anomala* and *H. jadinii*), and *Brettanomyces* (e.g., *B. lambicus* and *B. anomalus*). Examples of useful bacteria include, but are not limited to, *Escherichia*, *Enterobacter*, *Azotobacter*, *Erwinia*, *Klebsiella*.

[0130] Typically, the polynucleotide that encodes the fusion protein is placed under the control of a promoter that is functional in the desired host cell. An extremely wide variety of  
25 promoters are well known, and can be used in the expression vectors of the invention, depending on the particular application. Ordinarily, the promoter selected depends upon the cell in which the promoter is to be active. Other expression control sequences such as ribosome binding sites, transcription termination sites and the like are also optionally included. Constructs that include one or more of these control sequences are termed  
30 “expression cassettes.” Accordingly, the invention provides expression cassettes into which the nucleic acids that encode fusion proteins are incorporated for high level expression in a desired host cell.

[0131] Expression control sequences that are suitable for use in a particular host cell are often obtained by cloning a gene that is expressed in that cell. Commonly used prokaryotic control sequences, which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such  
5 commonly used promoters as the beta-lactamase (penicillinase) and lactose (*lac*) promoter systems (Change *et al.*, *Nature* (1977) 198: 1056), the tryptophan (*trp*) promoter system (Goeddel *et al.*, *Nucleic Acids Res.* (1980) 8: 4057), the *tac* promoter (DeBoer, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* (1983) 80:21-25); and the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Shimatake *et al.*, *Nature* (1981) 292: 128). The particular promoter  
10 system is not critical to the invention, any available promoter that functions in prokaryotes can be used.

[0132] For expression of recombinant eukaryotic glycosyltransferases in prokaryotic cells other than *E. coli*, a promoter that functions in the particular prokaryotic species is required. Such promoters can be obtained from genes that have been cloned from the species, or  
15 heterologous promoters can be used. For example, the hybrid *trp-lac* promoter functions in *Bacillus* in addition to *E. coli*.

[0133] A ribosome binding site (RBS) is conveniently included in the expression cassettes of the invention. An RBS in *E. coli*, for example, consists of a nucleotide sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (Shine and  
20 Dalgarno, *Nature* (1975) 254: 34; Steitz, *In Biological regulation and development: Gene expression* (ed. R.F. Goldberger), vol. 1, p. 349, 1979, Plenum Publishing, NY).

[0134] For expression of the recombinant eukaryotic glycosyltransferases in yeast, convenient promoters include GAL1-10 (Johnson and Davies (1984) *Mol. Cell. Biol.* 4:1440-1448) ADH2 (Russell *et al.* (1983) *J. Biol. Chem.* 258:2674-2682), PHO5 (*EMBO J.* (1982)  
25 6:675-680), and MF $\alpha$  (Herskowitz and Oshima (1982) in *The Molecular Biology of the Yeast Saccharomyces* (eds. Strathern, Jones, and Broach) Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp. 181-209). Another suitable promoter for use in yeast is the ADH2/GAPDH hybrid promoter as described in Cousens *et al.*, *Gene* 61:265-275 (1987). For filamentous fungi such as, for example, strains of the fungi *Aspergillus* (McKnight *et al.*, U.S. Patent No.  
30 4,935,349), examples of useful promoters include those derived from *Aspergillus nidulans* glycolytic genes, such as the ADH3 promoter (McKnight *et al.*, *EMBO J.* 4: 2093 2099



(1985)) and the *tpiA* promoter. An example of a suitable terminator is the ADH3 terminator (McKnight *et al.*).

[0135] Suitable constitutive promoters for use in plants include, for example, the cauliflower mosaic virus (CaMV) 35S transcription initiation region and region VI promoters, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, and other promoters active in plant cells that are known to those of skill in the art. Other suitable promoters include the full-length transcript promoter from Figwort mosaic virus, actin promoters, histone promoters, tubulin promoters, or the mannopine synthase promoter (MAS). Other constitutive plant promoters include various ubiquitin or polyubiquitin promoters derived from, *inter alia*, Arabidopsis (Sun and Callis, *Plant J.*, 11(5):1017-1027 (1997)), the mas, Mac or DoubleMac promoters (described in United States Patent No. 5,106,739 and by Comai *et al.*, *Plant Mol. Biol.* 15:373-381 (1990)) and other transcription initiation regions from various plant genes known to those of skill in the art. Useful promoters for plants also include those obtained from Ti- or Ri-plasmids, from plant cells, plant viruses or other hosts where the promoters are found to be functional in plants. Bacterial promoters that function in plants, and thus are suitable for use in the methods of the invention include the octopine synthetase promoter, the nopaline synthase promoter, and the mannopine synthetase promoter. Suitable endogenous plant promoters include the ribulose-1,6-bisphosphate (RUBP) carboxylase small subunit (ssu) promoter, the ( $\alpha$ -conglycinin promoter, the phaseolin promoter, the ADH promoter, and heat-shock promoters.

[0136] Either constitutive or regulated promoters can be used in the present invention. Regulated promoters can be advantageous because the host cells can be grown to high densities before expression of the fusion proteins is induced. High level expression of heterologous proteins slows cell growth in some situations. An inducible promoter is a promoter that directs expression of a gene where the level of expression is alterable by environmental or developmental factors such as, for example, temperature, pH, anaerobic or aerobic conditions, light, transcription factors and chemicals. Such promoters are referred to herein as "inducible" promoters, which allow one to control the timing of expression of the glycosyltransferase or enzyme involved in nucleotide sugar synthesis. For *E. coli* and other bacterial host cells, inducible promoters are known to those of skill in the art. These include, for example, the *lac* promoter, the bacteriophage lambda P<sub>L</sub> promoter, the hybrid *trp-lac* promoter (Amann *et al.* (1983) *Gene* 25: 167; de Boer *et al.* (1983) *Proc. Nat'l. Acad. Sci. USA* 80: 21), and the bacteriophage T7 promoter (Studier *et al.* (1986) *J. Mol. Biol.*; Tabor *et*

*al.* (1985) *Proc. Nat'l. Acad. Sci. USA* 82: 1074-8). These promoters and their use are discussed in Sambrook *et al.*, *supra*. A particularly preferred inducible promoter for expression in prokaryotes is a dual promoter that includes a *tac* promoter component linked to a promoter component obtained from a gene or genes that encode enzymes involved in galactose metabolism (*e.g.*, a promoter from a UDPgalactose 4-epimerase gene (*galE*)). The dual *tac-gal* promoter, which is described in PCT Patent Application Publ. No. WO98/20111, provides a level of expression that is greater than that provided by either promoter alone.

[0137] Inducible promoters for use in plants are known to those of skill in the art (*see, e.g.*, references cited in Kuhlemeier *et al* (1987) *Ann. Rev. Plant Physiol.* 38:221), and include those of the 1,5-ribulose biphosphate carboxylase small subunit genes of *Arabidopsis thaliana* (the "ssu" promoter), which are light-inducible and active only in photosynthetic tissue.

[0138] Inducible promoters for other organisms are also well known to those of skill in the art. These include, for example, the arabinose promoter, the *lacZ* promoter, the metallothionein promoter, and the heat shock promoter, as well as many others.

[0139] A construct that includes a polynucleotide of interest operably linked to gene expression control signals that, when placed in an appropriate host cell, drive expression of the polynucleotide is termed an "expression cassette." Expression cassettes that encode the fusion proteins of the invention are often placed in expression vectors for introduction into the host cell. The vectors typically include, in addition to an expression cassette, a nucleic acid sequence that enables the vector to replicate independently in one or more selected host cells. Generally, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria. For instance, the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria. Alternatively, the vector can replicate by becoming integrated into the host cell genomic complement and being replicated as the cell undergoes DNA replication. A preferred expression vector for expression of the enzymes is in bacterial cells is pTGK, which includes a dual *tac-gal* promoter and is described in PCT Patent Application Publ. NO. WO98/20111.

[0140] It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in

response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA  $\alpha$ -amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences.

[0141] The construction of polynucleotide constructs generally requires the use of vectors able to replicate in bacteria. A plethora of kits are commercially available for the purification of plasmids from bacteria (see, for example, EasyPrepJ, FlexiPrepJ, both from Pharmacia Biotech; StrataCleanJ, from Stratagene; and, QIAexpress Expression System, Qiagen). The isolated and purified plasmids can then be further manipulated to produce other plasmids, and used to transfect cells. Cloning in *Streptomyces* or *Bacillus* is also possible.

[0142] Selectable markers are often incorporated into the expression vectors used to express the polynucleotides of the invention. These genes can encode a gene product, such as a protein, necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics or other toxins, such as ampicillin, neomycin, kanamycin, chloramphenicol, or tetracycline. Alternatively, selectable markers may encode proteins that complement auxotrophic deficiencies or supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. Often, the vector will have one selectable marker that is functional in, e.g., *E. coli*, or other cells in which the vector is replicated prior to being introduced into the host cell. A number of selectable markers are known to those of skill in the art and are described for instance in Sambrook *et al.*, *supra*. A preferred selectable marker for use in bacterial cells is a kanamycin resistance marker (Vieira and Messing, *Gene* 19: 259 (1982)). Use of kanamycin selection is advantageous over, for example, ampicillin selection because ampicillin is quickly degraded by  $\beta$ -lactamase in culture medium, thus removing selective pressure and allowing the culture to become overgrown with cells that do not contain the vector.

[0143] Construction of suitable vectors containing one or more of the above listed components employs standard ligation techniques as described in the references cited above. Isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the plasmids required. To confirm correct sequences in plasmids constructed, the

plasmids can be analyzed by standard techniques such as by restriction endonuclease digestion, and/or sequencing according to known methods. Molecular cloning techniques to achieve these ends are known in the art. A wide variety of cloning and *in vitro* amplification methods suitable for the construction of recombinant nucleic acids are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Volume 152, Academic Press, Inc., San Diego, CA (Berger); and Current Protocols in Molecular Biology, F.M. Ausubel *et al.*, eds., *Current Protocols*, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1998 Supplement) (Ausubel).

[0144] A variety of common vectors suitable for use as starting materials for constructing the expression vectors of the invention are well known in the art. For cloning in bacteria, common vectors include pBR322 derived vectors such as pBLUESCRIPT™, and  $\lambda$ -phage derived vectors. In yeast, vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp series plasmids) and pGPD-2. Expression in mammalian cells can be achieved using a variety of commonly available plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses).

[0145] The methods for introducing the expression vectors into a chosen host cell are not particularly critical, and such methods are known to those of skill in the art. For example, the expression vectors can be introduced into prokaryotic cells, including *E. coli*, by calcium chloride transformation, and into eukaryotic cells by calcium phosphate treatment or electroporation. Other transformation methods are also suitable.

[0146] Translational coupling may be used to enhance expression. The strategy uses a short upstream open reading frame derived from a highly expressed gene native to the translational system, which is placed downstream of the promoter, and a ribosome binding site followed after a few amino acid codons by a termination codon. Just prior to the termination codon is a second ribosome binding site, and following the termination codon is a start codon for the initiation of translation. The system dissolves secondary structure in the RNA, allowing for the efficient initiation of translation. See Squires, *et. al.* (1988), *J. Biol. Chem.* 263: 16297-16302.

[0147] The recombinant eukaryotic glycosyltransferases of the invention can also be further linked to other bacterial proteins. This approach often results in high yields, because normal prokaryotic control sequences direct transcription and translation. In *E. coli*, *lacZ* fusions are often used to express heterologous proteins. Suitable vectors are readily  
5 available, such as the pUR, pEX, and pMR100 series (*see, e.g., Sambrook et al., supra.*). For certain applications, it may be desirable to cleave the non-glycosyltransferase and/or accessory enzyme amino acids from the fusion protein after purification. This can be accomplished by any of several methods known in the art, including cleavage by cyanogen bromide, a protease, or by Factor X<sub>a</sub> (*see, e.g., Sambrook et al., supra.; Itakura et al., Science*  
10 (1977) 198: 1056; Goeddel *et al., Proc. Natl. Acad. Sci. USA* (1979) 76: 106; Nagai *et al., Nature* (1984) 309: 810; Sung *et al., Proc. Natl. Acad. Sci. USA* (1986) 83: 561). Cleavage sites can be engineered into the gene for the fusion protein at the desired point of cleavage.

[0148] More than one recombinant eukaryotic glycosyltransferase may be expressed in a single host cell by placing multiple transcriptional cassettes in a single expression vector, or  
15 by utilizing different selectable markers for each of the expression vectors which are employed in the cloning strategy.

[0149] A suitable system for obtaining recombinant proteins from *E. coli* which maintains the integrity of their N-termini has been described by Miller *et al. Biotechnology* 7:698-704 (1989). In this system, the gene of interest is produced as a C-terminal fusion to the first 76  
20 residues of the yeast ubiquitin gene containing a peptidase cleavage site. Cleavage at the junction of the two moieties results in production of a protein having an intact authentic N-terminal residue.

[0150] The expression vectors of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for *E. coli* and calcium  
25 phosphate treatment or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the *amp*, *gpt*, *neo* and *hyg* genes.

## **VI. Proteins and protein purification**

[0151] The recombinant eukaryotic glycosyltransferase proteins can be purified according  
30 to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (*see, generally, R. Scopes, Protein Purification, Springer-Verlag, N.Y. (1982), Deutscher, Methods in Enzymology Vol. 182:*

*Guide to Protein Purification.*, Academic Press, Inc. N.Y. (1990)). Substantially pure compositions of at least about 70 to 90%, homogeneity are preferred; more preferably at least 91%, 92%, 93%, 94%, 95%, 96%, or 97%; and 98 to 99% or more homogeneity are most preferred. The purified proteins may also be used, *e.g.*, as immunogens for antibody production.

[0152] To facilitate purification of the recombinant eukaryotic glycosyltransferase proteins of the invention, the nucleic acids that encode the recombinant eukaryotic glycosyltransferase proteins can also include a coding sequence for an epitope or "tag" for which an affinity binding reagent is available, *i.e.* a purification tag. Examples of suitable epitopes include the myc and V-5 reporter genes; expression vectors useful for recombinant production of fusion proteins having these epitopes are commercially available (*e.g.*, Invitrogen (Carlsbad CA) vectors pcDNA3.1/Myc-His and pcDNA3.1/V5-His are suitable for expression in mammalian cells). Additional expression vectors suitable for attaching a tag to the fusion proteins of the invention, and corresponding detection systems are known to those of skill in the art, and several are commercially available (*e.g.*, FLAG" (Kodak, Rochester NY).

Another example of a suitable tag is a polyhistidine sequence, which is capable of binding to metal chelate affinity ligands. Typically, six adjacent histidines are used, although one can use more or less than six. Suitable metal chelate affinity ligands that can serve as the binding moiety for a polyhistidine tag include nitrilo-tri-acetic acid (NTA) (Hochuli, E. (1990)

"Purification of recombinant proteins with metal chelating adsorbents" In Genetic Engineering: Principles and Methods, J.K. Setlow, Ed., Plenum Press, NY; commercially available from Qiagen (Santa Clarita, CA)).

[0153] Purification tags also include maltose binding domains and starch binding domains. Purification of maltose binding domain proteins is known to those of skill in the art. Starch binding domains are described in WO 99/15636, herein incorporated by reference. Affinity purification of a fusion protein comprising a starch binding domain using a betacylodextrin (BCD)-derivatized resin is described in USSN 60/468,374, filed May 5, 2003, herein incorporated by reference in its entirety.

[0154] Other haptens that are suitable for use as tags are known to those of skill in the art and are described, for example, in the Handbook of Fluorescent Probes and Research Chemicals (6th Ed., Molecular Probes, Inc., Eugene OR). For example, dinitrophenol (DNP), digoxigenin, barbiturates (see, *e.g.*, US Patent No. 5,414,085), and several types of

fluorophores are useful as haptens, as are derivatives of these compounds. Kits are commercially available for linking haptens and other moieties to proteins and other molecules. For example, where the hapten includes a thiol, a heterobifunctional linker such as SMCC can be used to attach the tag to lysine residues present on the capture reagent.

5 [0155] One of skill would recognize that modifications can be made to the glycosyltransferase catalytic or functional domains and/or accessory enzyme catalytic domains without diminishing their biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the catalytic domain into a fusion protein. Such modifications are well known to those of skill in the art and include, for  
10 example, the addition of codons at either terminus of the polynucleotide that encodes the catalytic domain to provide, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (*e.g.*, poly His) placed on either terminus to create conveniently located restriction enzyme sites or termination codons or purification sequences.

## 15 VII. Uses of refolded glycosyltransferases

[0156] The invention provides recombinant eukaryotic glycosyltransferase proteins and methods of using the recombinant eukaryotic glycosyltransferase proteins to enzymatically synthesize glycoproteins, glycolipids, and oligosaccharide moieties, and to glycoPEGylate glycoproteins. The glycosyltransferase reactions of the invention take place in a reaction  
20 medium comprising at least one glycosyltransferase, acceptor substrate, and donor substrate, and typically a soluble divalent metal cation. In some embodiments, accessory enzymes and substrates for the accessory enzyme catalytic moiety are also present, so that the accessory enzymes can synthesize the donor substrate for the glycosyltransferase. The recombinant eukaryotic glycosyltransferase proteins and methods of the present invention rely on the use  
25 the recombinant eukaryotic glycosyltransferase proteins to catalyze the addition of a saccharide to an acceptor substrate.

[0157] A number of methods of using glycosyltransferases to synthesize glycoproteins and glycolipids having desired oligosaccharide moieties are known. Exemplary methods are described, for instance, WO 96/32491, Ito *et al.* (1993) *Pure Appl. Chem.* 65: 753, and US  
30 Patents 5, 352,670, 5,374,541, and 5,545,553.

[0158] The recombinant eukaryotic glycosyltransferase proteins prepared as described herein can be used in combination with additional glycosyltransferases, that may or may not

have required refolding for activity. For example, one can use a combination of refolded recombinant eukaryotic glycosyltransferase protein and a bacterial glycosyltransferase, which may or may not have been refolded after isolation from a host cell. Similarly, the recombinant eukaryotic glycosyltransferase can be used with recombinant accessory enzymes, which may or may not be part of the fusion protein.

[0159] The products produced by the above processes can be used without purification. In some embodiments, oligosaccharides are produced. Standard, well known techniques, for example, thin or thick layer chromatography, ion exchange chromatography, or membrane filtration can be used for recovery of glycosylated saccharides. Also, for example, membrane filtration, utilizing a nanofiltration or reverse osmotic membrane as described in commonly assigned AU Patent No. 735695 may be used. As a further example, membrane filtration wherein the membranes have a molecular weight cutoff of about 1000 to about 10,000 can be used to remove proteins. As another example, nanofiltration or reverse osmosis can then be used to remove salts. Nanofilter membranes are a class of reverse osmosis membranes which pass monovalent salts but retain polyvalent salts and uncharged solutes larger than about 200 to about 1000 Daltons, depending upon the membrane used. Thus, for example, the oligosaccharides produced by the compositions and methods of the present invention can be retained in the membrane and contaminating salts will pass through.

#### **VIII. Donor substrate/Acceptor substrates**

[0160] Suitable donor substrates used by the recombinant glycosyltransferase fusion proteins and methods of the invention include, but are not limited to, UDP-Glc, UDP-GlcNAc, UDP-Gal, UDP-GalNAc, GDP-Man, GDP-Fuc, UDP-GlcUA, and CMP-sialic acid. Guo *et al.*, *Applied Biochem. and Biotech.* 68: 1-20 (1997)

[0161] Suitable acceptor substrates used by the recombinant glycosyltransferase fusion proteins and methods of the invention include, but are not limited to, polysaccharides, oligosaccharides, proteins, lipids, gangliosides and other biological structures (*e.g.*, whole cells) that can be modified by the methods of the invention. Exemplary structures, which can be modified by the methods of the invention include any of a number of glycolipids, glycoproteins and carbohydrate structures on cells known to those skilled in the art as set forth in Table 1.



**Table 1**

<u>Hormones and Growth Factors</u>	<u>Receptors and Chimeric Receptors</u>
<ul style="list-style-type: none"> <li>• G-CSF</li> <li>• GM-CSF</li> <li>• TPO</li> <li>• EPO</li> <li>• EPO variants</li> <li>• <math>\alpha</math>-TNF</li> <li>• Leptin</li> </ul>	<ul style="list-style-type: none"> <li>• CD4</li> <li>• Tumor Necrosis Factor (TNF) receptor</li> <li>• Alpha-CD20</li> <li>• MAb-CD20</li> <li>• MAb-alpha-CD3</li> <li>• MAb-TNF receptor</li> <li>• MAb-CD4</li> <li>• PSGL-1</li> <li>• MAb-PSGL-1</li> <li>• Complement</li> <li>• GlyCAM or its chimera</li> <li>• N-CAM or its chimera</li> <li>• LFA-3</li> <li>• CTLA-IV</li> </ul>
<u>Enzymes and Inhibitors</u> <ul style="list-style-type: none"> <li>• t-PA</li> <li>• t-PA variants</li> <li>• Urokinase</li> <li>• Factors VII, VIII, IX, X</li> <li>• DNase</li> <li>• Glucocerebrosidase</li> <li>• Hirudin</li> <li>• <math>\alpha</math>1 antitrypsin</li> <li>• Antithrombin III</li> </ul>	<u>Monoclonal Antibodies (Immunoglobulins)</u> <ul style="list-style-type: none"> <li>• MAb-anti-RSV</li> <li>• MAb-anti-IL-2 receptor</li> <li>• MAb-anti-CEA</li> <li>• MAb-anti-platelet IIb/IIIa receptor</li> <li>• MAb-anti-EGF</li> <li>• MAb-anti-Her-2 receptor</li> </ul>
<u>Cytokines and Chimeric Cytokines</u> <ul style="list-style-type: none"> <li>• Interleukin-1 (IL-1), 1B, 2, 3, 4</li> <li>• Interferon-<math>\alpha</math> (IFN-<math>\alpha</math>)</li> <li>• IFN-<math>\alpha</math>-2b</li> <li>• IFN-<math>\beta</math></li> <li>• IFN-<math>\gamma</math></li> <li>• Chimeric diphtheria toxin-IL-2</li> </ul>	<u>Cells</u> <ul style="list-style-type: none"> <li>• Red blood cells</li> <li>• White blood cells (<i>e.g.</i>, T cells, B cells, dendritic cells, macrophages, NK cells, neutrophils, monocytes and the like <ul style="list-style-type: none"> <li>• Stem cells</li> </ul> </li> </ul>

[0162] Examples of suitable acceptor substrates used in fucosyltransferase-catalyzed reactions, and examples of suitable acceptor substrates used in sialyltransferase-catalyzed reactions are described in Guo *et al.*, *Applied Biochem. and Biotech.* **68**: 1-20 (1997), but are not limited thereto.

## 5 IX. Glycosyltransferase reactions

[0163] The recombinant eukaryotic glycosyltransferase proteins, acceptor substrates, donor substrates and other reaction mixture ingredients are combined by admixture in an aqueous reaction medium. The medium generally has a pH value of about 5 to about 8.5. The selection of a medium is based on the ability of the medium to maintain pH value at the  
10 desired level. Thus, in some embodiments, the medium is buffered to a pH value of about 7.5. If a buffer is not used, the pH of the medium should be maintained at about 5 to 8.5, depending upon the particular glycosyltransferase used. For fucosyltransferases, the pH range is preferably maintained from about 6.0 to 8.0. For sialyltransferases, the range is preferably from about 5.5 to about 7.5.

15 [0164] Enzyme amounts or concentrations are expressed in activity units, which is a measure of the initial rate of catalysis. One activity unit catalyzes the formation of 1  $\mu\text{mol}$  of product per minute at a given temperature (typically 37°C) and pH value (typically 7.5). Thus, 10 units of an enzyme is a catalytic amount of that enzyme where 10  $\mu\text{mol}$  of substrate are converted to 10  $\mu\text{mol}$  of product in one minute at a temperature of 37 °C and a pH value  
20 of 7.5.

[0165] The reaction mixture may include divalent metal cations ( $\text{Mg}^{2+}$ ,  $\text{Mn}^{2+}$ ). The reaction medium may also comprise solubilizing detergents (*e.g.*, Triton or SDS) and organic solvents such as methanol or ethanol, if necessary. The enzymes can be utilized free in solution or can be bound to a support such as a polymer. The reaction mixture is thus  
25 substantially homogeneous at the beginning, although some precipitate can form during the reaction.

[0166] The temperature at which an above process is carried out can range from just above freezing to the temperature at which the most sensitive enzyme denatures. That temperature range is preferably about 0°C to about 45°C, and more preferably at about 20°C to about  
30 37°C.

[0167] The reaction mixture so formed is maintained for a period of time sufficient to obtain the desired high yield of desired oligosaccharide determinants present on oligosaccharide groups attached to the glycoprotein to be glycosylated. For large-scale preparations, the reaction will often be allowed to proceed for between about 0.5-240 hours, and more typically between about 1-18 hours.

[0168] One or more of the glycosyltransferase reactions can be carried out as part of a glycosyltransferase cycle. Preferred conditions and descriptions of glycosyltransferase cycles have been described. A number of glycosyltransferase cycles (for example, sialyltransferase cycles, galactosyltransferase cycles, and fucosyltransferase cycles) are described in U.S. Patent No. 5,374,541 and WO 9425615 A. Other glycosyltransferase cycles are described in Ichikawa *et al. J. Am. Chem. Soc.* 114:9283 (1992), Wong *et al. J. Org. Chem.* **57**: 4343 (1992), DeLuca, *et al., J. Am. Chem. Soc.* 117:5869-5870 (1995), and Ichikawa *et al.* In *Carbohydrates and Carbohydrate Polymers*. Yaltami, ed. (ATL Press, 1993).

[0169] Other glycosyltransferases can be substituted into similar transferase cycles as have been described in detail for the fucosyltransferases and sialyltransferases. In particular, the glycosyltransferase can also be, for instance, glucosyltransferases, *e.g.*, Alg8 (Stagljev *et al., Proc. Natl. Acad. Sci. USA* 91:5977 (1994)) or Alg5 (Heesen *et al. Eur. J. Biochem.* 224:71 (1994)), N-acetylgalactosaminyltransferases such as, for example,  $\alpha$ (1,3) N-acetylgalactosaminyltransferase,  $\beta$ (1,4) N-acetylgalactosaminyltransferases (Nagata *et al. J. Biol. Chem.* 267:12082-12089 (1992) and Smith *et al. J. Biol. Chem.* 269:15162 (1994)) and polypeptide N-acetylgalactosaminyltransferase (Homa *et al. J. Biol. Chem.* 268:12609 (1993)). Suitable N-acetylglucosaminyltransferases include GnTI (2.4.1.101, Hull *et al., BBRC* 176:608 (1991)), GnTII, and GnTIII (Ihara *et al. J. Biochem.* 113:692 (1993)), GnTV (Shoreiban *et al. J. Biol. Chem.* 268: 15381 (1993)), O-linked N-acetylglucosaminyltransferase (Bierhuizen *et al. Proc. Natl. Acad. Sci. USA* 89:9326 (1992)), N-acetylglucosamine-1-phosphate transferase (Rajput *et al. Biochem J.* 285:985 (1992), and hyaluronan synthase. Suitable mannosyltransferases include  $\alpha$ (1,2) mannosyltransferase,  $\alpha$ (1,3) mannosyltransferase,  $\beta$ (1,4) mannosyltransferase, Dol-P-Man synthase, OCh1, and Pmt1.

[0170] For the above glycosyltransferase cycles, the concentrations or amounts of the various reactants used in the processes depend upon numerous factors including reaction conditions such as temperature and pH value, and the choice and amount of acceptor

saccharides to be glycosylated. Because the glycosylation process permits regeneration of activating nucleotides, activated donor sugars and scavenging of produced PPi in the presence of catalytic amounts of the enzymes, the process is limited by the concentrations or amounts of the stoichiometric substrates discussed before. The upper limit for the concentrations of reactants that can be used in accordance with the method of the present invention is determined by the solubility of such reactants.

[0171] Preferably, the concentrations of activating nucleotides, phosphate donor, the donor sugar and enzymes are selected such that glycosylation proceeds until the acceptor is consumed. The considerations discussed below, while in the context of a sialyltransferase, are generally applicable to other glycosyltransferase cycles.

[0172] Each of the enzymes is present in a catalytic amount. The catalytic amount of a particular enzyme varies according to the concentration of that enzyme's substrate as well as to reaction conditions such as temperature, time and pH value. Means for determining the catalytic amount for a given enzyme under preselected substrate concentrations and reaction conditions are well known to those of skill in the art.

## **X. Multienzyme oligosaccharide synthesis**

[0173] As discussed above, in some embodiments, two or more enzymes may be used to form a desired oligosaccharide determinant on a glycoprotein or glycolipid. For example, a particular oligosaccharide determinant might require addition of a galactose, a sialic acid, and a fucose in order to exhibit a desired activity. Accordingly, the invention provides methods in which two or more enzymes, *e.g.*, glycosyltransferases, trans-sialidases, or sulfotransferases, are used to obtain high-yield synthesis of a desired oligosaccharide determinant.

[0174] In a particularly preferred embodiment, one of the enzymes used is a sulfotransferase which sulfonates the saccharide or the peptide. Even more preferred is the use of a sulfotransferase to prepare a ligand for a selectin (Kimura *et al.*, *Proc Natl Acad Sci U S A* 96(8):4530-5 (1999)).

[0175] In some cases, a glycoprotein- or glycolipid linked oligosaccharide will include an acceptor substrate for the particular glycosyltransferase of interest upon *in vivo* biosynthesis of the glycoprotein or glycolipid. Such glycoproteins or glycolipids can be glycosylated using the recombinant glycosyltransferase fusion proteins and methods of the invention without prior modification of the glycosylation pattern of the glycoprotein or glycolipid,

respectively. In other cases, however, a glycoprotein or glycolipid of interest will lack a suitable acceptor substrate. In such cases, the methods of the invention can be used to alter the glycosylation pattern of the glycoprotein or glycolipid so that the glycoprotein-or glycolipid-linked oligosaccharides then include an acceptor substrate for the

glycosyltransferase-catalyzed attachment of a preselected saccharide unit of interest to form a desired oligosaccharide moiety.

[0176] Glycoprotein- or glycolipid linked oligosaccharides optionally can be first “trimmed,” either in whole or in part, to expose either an acceptor substrate for the glycosyltransferase or a moiety to which one or more appropriate residues can be added to obtain a suitable acceptor substrate. Enzymes such as glycosyltransferases and endoglycosidases are useful for the attaching and trimming reactions. For example, a glycoprotein that displays “high mannose”-type oligosaccharides can be subjected to trimming by a mannosidase to obtain an acceptor substrate that, upon attachment of one or more preselected saccharide units, forms the desired oligosaccharide determinant.

[0177] The methods are also useful for synthesizing a desired oligosaccharide moiety on a protein or lipid that is unglycosylated in its native form. A suitable acceptor substrate for the corresponding glycosyltransferase can be attached to such proteins or lipids prior to glycosylation using the methods of the present invention. *See, e.g.*, US Patent No. 5,272,066 for methods of obtaining polypeptides having suitable acceptors for glycosylation.

[0178] Thus, in some embodiments, the invention provides methods for *in vitro* sialylation of saccharide groups present on a glycoconjugate that first involves modifying the glycoconjugate to create a suitable acceptor.

## **XI. Conjugation of modified sugars to peptides**

[0179] The modified sugars are conjugated to a glycosylated or non-glycosylated peptide or protein using an appropriate enzyme to mediate the conjugation. Preferably, the concentrations of the modified donor sugar(s), enzyme(s) and acceptor peptide(s) or protein(s) are selected such that glycosylation proceeds until the acceptor is consumed. The considerations discussed below, while set forth in the context of a sialyltransferase, are generally applicable to other glycosyltransferase reactions.

[0180] A number of methods of using glycosyltransferases to synthesize desired oligosaccharide structures are known and are generally applicable to the instant invention.

Exemplary methods are described, for instance, WO 96/32491, Ito *et al.*, *Pure Appl. Chem.* **65**: 753 (1993), and U.S. Pat. Nos. 5,352,670, 5,374,541, and 5,545,553.

[0181] In some embodiments, an endoglycosidase is used in the reaction in combination with glycosyltransferases. The enzymes are used to alter a saccharide structure on the peptide at any point either before or after the addition of the modified sugar to the peptide.

[0182] In another embodiment, the method makes use of one or more exo- or endoglycosidase. The glycosidase is typically a mutant, which is engineered to form glycosyl bonds rather than rupture them. The mutant glycanase typically includes a substitution of an amino acid residue for an active site acidic amino acid residue. For example, when the endoglycanase is endo-H, the substituted active site residues will typically be Asp at position 130, Glu at position 132 or a combination thereof. The amino acids are generally replaced with serine, alanine, asparagine, or glutamine.

[0183] The mutant enzyme catalyzes the reaction, usually by a synthesis step that is analogous to the reverse reaction of the endoglycanase hydrolysis step. In these embodiments, the glycosyl donor molecule (*e.g.*, a desired oligo- or mono-saccharide structure) contains a leaving group and the reaction proceeds with the addition of the donor molecule to a GlcNAc residue on the protein. For example, the leaving group can be a halogen, such as fluoride. In other embodiments, the leaving group is a Asn, or a Asn-peptide moiety. In yet further embodiments, the GlcNAc residue on the glycosyl donor molecule is modified. For example, the GlcNAc residue may comprise a 1,2 oxazoline moiety.

[0184] In a preferred embodiment, each of the enzymes utilized to produce a conjugate of the invention are present in a catalytic amount. The catalytic amount of a particular enzyme varies according to the concentration of that enzyme's substrate as well as to reaction conditions such as temperature, time and pH value. Means for determining the catalytic amount for a given enzyme under preselected substrate concentrations and reaction conditions are well known to those of skill in the art.

[0185] The temperature at which an above process is carried out can range from just above freezing to the temperature at which the most sensitive enzyme denatures. Preferred temperature ranges are about 0 °C to about 55 °C, and more preferably about 20 °C to about 30 °C. In another exemplary embodiment, one or more components of the present method are conducted at an elevated temperature using a thermophilic enzyme.

[0186] The reaction mixture is maintained for a period of time sufficient for the acceptor to be glycosylated, thereby forming the desired conjugate. Some of the conjugate can often be detected after a few hours, with recoverable amounts usually being obtained within 24 hours or less. Those of skill in the art understand that the rate of reaction is dependent on a number of variable factors (*e.g.*, enzyme concentration, donor concentration, acceptor concentration, temperature, solvent volume), which are optimized for a selected system.

[0187] The present invention also provides for the industrial-scale production of modified peptides. As used herein, an industrial scale generally produces at least one gram of finished, purified conjugate.

[0188] In the discussion that follows, the invention is exemplified by the conjugation of modified sialic acid moieties to a glycosylated peptide. The exemplary modified sialic acid is labeled with PEG. The focus of the following discussion on the use of PEG-modified sialic acid and glycosylated peptides is for clarity of illustration and is not intended to imply that the invention is limited to the conjugation of these two partners. One of skill understands that the discussion is generally applicable to the additions of modified glycosyl moieties other than sialic acid. Moreover, the discussion is equally applicable to the modification of a glycosyl unit with agents other than PEG including other water-soluble polymers, therapeutic moieties, and biomolecules.

[0189] An enzymatic approach can be used for the selective introduction of PEGylated or PPGylated carbohydrates onto a peptide or glycopeptide. The method utilizes modified sugars containing PEG, PPG, or a masked reactive functional group, and is combined with the appropriate glycosyltransferase or glycosynthase. By selecting the glycosyltransferase that will make the desired carbohydrate linkage and utilizing the modified sugar as the donor substrate, the PEG or PPG can be introduced directly onto the peptide backbone, onto existing sugar residues of a glycopeptide or onto sugar residues that have been added to a peptide.

[0190] An acceptor for the sialyltransferase is present on the peptide to be modified by the methods of the present invention either as a naturally occurring structure or one placed there recombinantly, enzymatically or chemically. Suitable acceptors, include, for example, galactosyl acceptors such as Gal $\beta$ 1,4GlcNAc, Gal $\beta$ 1,4GalNAc, Gal $\beta$ 1,3GalNAc, lacto-N-tetraose, Gal $\beta$ 1,3GlcNAc, Gal $\beta$ 1,3Ara, Gal $\beta$ 1,6GlcNAc, Gal $\beta$ 1,4Glc (lactose), and other

acceptors known to those of skill in the art (*see, e.g., Paulson et al., J. Biol. Chem.* **253**: 5617-5624 (1978)).

[0191] In one embodiment, an acceptor for the sialyltransferase is present on the glycopeptide to be modified upon *in vivo* synthesis of the glycopeptide. Such glycopeptides  
5 can be sialylated using the claimed methods without prior modification of the glycosylation pattern of the glycopeptide. Alternatively, the methods of the invention can be used to sialylate a peptide that does not include a suitable acceptor; one first modifies the peptide to include an acceptor by methods known to those of skill in the art. In an exemplary embodiment, a GalNAc residue is added by the action of a GalNAc transferase.

10 [0192] In an exemplary embodiment, the galactosyl acceptor is assembled by attaching a galactose residue to an appropriate acceptor linked to the peptide, *e.g.,* a GlcNAc. The method includes incubating the peptide to be modified with a reaction mixture that contains a suitable amount of a galactosyltransferase (*e.g.,* gal $\beta$ 1,3 or gal $\beta$ 1,4), and a suitable galactosyl donor (*e.g.,* UDP-galactose). The reaction is allowed to proceed substantially to completion  
15 or, alternatively, the reaction is terminated when a preselected amount of the galactose residue is added. Other methods of assembling a selected saccharide acceptor will be apparent to those of skill in the art.

[0193] In yet another embodiment, glycopeptide-linked oligosaccharides are first “trimmed,” either in whole or in part, to expose either an acceptor for the sialyltransferase or  
20 a moiety to which one or more appropriate residues can be added to obtain a suitable acceptor. Enzymes such as glycosyltransferases and endoglycosidases (*see, for example* U.S. Patent No. 5,716,812) are useful for the attaching and trimming reactions.

[0194] Methods for conjugation of modified sugars to peptides or proteins are found *e.g.,* in USSN 60/328,523 filed October 10, 2001; USSN 60/387,292, filed June 7, 2002; USSN  
25 60/391,777 filed June 25, 2002; USSN 60/404,249 filed August 16, 2002; and PCT/US02/32263; each of which are herein incorporated by reference for all purposes.

## EXAMPLES

### Example 1: Refolding Rat Liver ST3GalIII Expressed in Bacteria.

#### *Refolding rat liver GST-ST3GalIII fusion protein*

30 [0195] Rat liver *N*-acetylglucosaminide  $\alpha$ -2,3-sialyltransferase (ST3GalIII) was cloned into pGEX-KT-Ext vector and expressed as GST-ST3-Gal III inclusion bodies in *E.coli* BL21 cells. Inclusion bodies were refolded using a GSH/GSSG redox system. The refolded



enzyme, GST-ST3-GalIII, was active and transferred sialic acid to an LNnT sugar substrate and to asialylated glycoproteins, for example, transferrin and Factor IX.

#### **Cloning ST3GalIII into pGEX-Xt-KT vector**

[0196] Rat liver ST3-GalIII gene was cloned into *Bam*H1 and *Eco*R1 sites of the pGEX-

5 KT-Ext vector after PCR Amplification using the following primers:

Sense Sial 5'Tm 5'-TTTGGATCCAAGCTACACTTACTCCAATGG  
Antisense: Sial 3' Whole 5'-TTTGAATTCTCAGATACCACTGCTTAAGTC

#### **Expression of GST-ST3GalIII in *E. coli* BL21 cells**

10 [0197] pGEX-ST3GalIII, an expression vector comprising the ST3GalIII GST fusion, was transformed into chemically competent *E. coli* BL21 cells. Single colonies were picked, inoculated into five ml LB media with 100 µg/ml carbenicillin, and grown overnight at 37°C with shaking. The next day, one ml of overnight culture was transferred into one liter of LB media with 100 µg/ml carbenicillin. Bacteria were grown until to an OD<sub>620</sub> of 0.7, then 150  
15 µM IPTG (final) was added to the medium. Bacteria were grown at 37°C for one to two hours more, then shifted to room temperature and grown overnight with shaking. Cells were harvested by centrifugation; bacterial pellets were resuspended in PBS buffer and lysed using a French Press. Soluble and insoluble fractions were separated by centrifugation for thirty minutes at 10,000 RPM in a Sorvall, SS 34 rotor at 4°C.

#### **20 Purification of the inclusion bodies**

[0198] Fifty ml of Novagen's Wash buffer (20 mM Tris.HCl, pH 7.5, 10 mM EDTA, 1 % Triton X-100) was added to the insoluble fraction, *i.e.*, the inclusion bodies (IB's). The insoluble fraction was vortexed to resuspend the pellet. The suspended IB's were centrifuged and washed at least twice by resuspending in Wash Buffer as above. Clean precipitates  
25 (IB's) were recovered and were stored at -20 °C until use.

#### **Refolding inclusion bodies**

[0199] The IB's were weighed (144 mg) and dissolved in Genotech IBS buffer (1.44 ml). The resuspended IB's were incubated at 4 °C for one hour in an Eppendorf centrifuge tube. Insoluble material was removed by centrifugation at maximum speed in an Eppendorf  
30 centrifuge. Solubilized IB's were diluted to 4 ml final volume. Refolding of GST-ST3GalIII was tested in refolding buffer solutions containing cyclodextrin, polyethylene glycol (PEG), ND SB-201, or a GSH/GSSG redox system. One ml of solubilized IB's were diluted rapidly by pipetting into the refolding solution, vigorously mixed for 30-40 seconds, and then gently

stirred for two hours at 4 °C. Three ml aliquots of the refolded GST-ST3GalIII solutions were dialyzed against cold PBS buffer or a buffer containing 50 mM Tris.HCL, pH 7.0; 100 mM NaCL; and 1 % glycerol using Pierce Slide-A-lyzers (MWCO:3.5 kDa,). After dialysis, the GST-ST3GalIII solutions were concentrated 3, 6 and 12 fold using Vivaspin 5 K

(VivaScience) concentrators in Jouan centrifuge at 4,000 rpm at 4°C.

**[0200]** After refolding and dialysis, the refolded GST-ST3GalIII proteins were analyzed by SDS-polyacrylamide gel electrophoresis. The GST-ST3GalIII fusion, with a molecular weight of about 63-64 kDa, was present under all refolding conditions. (Data not shown.)

### Sialylation of oligosaccharides using refolded GST-ST3 Gal III

**[0201]** Enzymatic assays using oligosaccharide substrates were carried out using CE-LIF (Capillary Electrophoresis-Laser Induced Fluorescence). Refolded ST3 Gal III enzymes were assayed for ability to transfer of sialic acid from CMP-NAN (cytidine 5-Monophosphate –β-D-sialic acid) to LNnT-APTS (Lacto-*N*-Neotetraose-9-aminopyrene 1-4, 6 trisulfonic acid) to form LSTd-APTS ( Lactosialic-Tetrasaccharide- d-APTS). Reactions were performed in 96 well microtiter plates in 100 μl of a buffer containing 20 mM MOPS, pH 6.5; 0.8 mM CMP-NAN; 22.1 mM LNnT; 25 μM LNnT-APTS; 2.5 mM MnCl<sub>2</sub>. Reactions were started by addition of 20 μl of refolded ST3 Gal III at 30 °C for thirty minutes. Reactions were quenched with a 1 to 25 dilution with water. The diluted reaction was analyzed by CE-LIF using an N-CHO coated capillary according to manufacturer's guide. Activities were calculated as the ratio of the normalized peak areas of LNnT-APTS to LSTd-APTS. Results comparing different refolding conditions are shown in Table 2. Two additional experiments using the GSH/GSSG system are shown in Table 3.

**Table 2.** GST-ST3-Gal III activities after screening different folding systems. The proteins were assayed directly without concentration.

Cyclodextrin	PEG	ND SB-201	GSH/GSSG
0	0	0	7.8 U/L*

\*Activities reported here are Units per L refolded enzyme.

**Table 3.** GST-ST3GalIII activities after two separate folding experiments using GSH/GSSG system.

GSH/GSSG	Conc	Activity
Refolding Trial 1	12x	182 U/L*
Refolding Trial 2	40x	531 U/L*

\*Activities reported here are Units per L refolded enzyme

### Sialylation of glycoproteins using refolded GST-ST3 Gal III

[0202] Twenty  $\mu$ L of asialylated Transferrin ( $2\mu\text{g}/\mu\text{L}$ ) or asialylated Factor IX ( $2\mu\text{g}/\mu\text{L}$ ), was added to fifty  $\mu$ L of a buffer containing 50mM Tris, pH 8.0; and 150 mM NaCl, with 10  $\mu$ L of 100 mM  $\text{MnCl}_2$ ; 10  $\mu$ L of 200mM CMP-NAN; and 0.05% sodium azide. The reaction mixture was incubated with 30  $\mu$ L refolded GST-ST3GalIII at  $30^\circ\text{C}$  overnight or longer with shaking at 250 rpm. After the reactions were stopped, the sialylated proteins were separated on pH 7-3 IEF (Isoelectric focusing gel, Invitrogen) and stained with Comassie Blue according to manufacturer's guideline. Both Transferrin and Factor IX were sialylated by GST-ST3GalIII. (Data not shown.)

### *Refolding a rat liver ST3GalIII fused to an MBP tag.*

[0203] Rat liver ST3GalIII was cloned into pMAL-c2x vector and expressed as a maltose binding protein (MBP) fusion, MBP-ST3GalIII, in inclusion bodies of *E.coli* TB1 cells. The refolded MBP-ST3GalIII was active and transferred sialic acid to LNnT, a sugar substrate, and to asialylated glycoproteins, for example asialo-transferrin.

### Cloning ST3GalIII into pMAL-c2x vector

[0204] The rat liver ST3-GalIII nucleic acid was cloned into *Bam*H1 and *Xba*I sites of the pMAL-c2x vector after PCR Amplification using the following primers:

Sense ST3BAMH1 5'-TAATGGATTCAAGCTACACTTACTCCAATGG  
Antisense: ST3XBA1 5'-GCGCTCTAGATCAGATACCACTGCTTAAGT

[0205] Nucleotides encoding amino acids 103-445, *e.g.*, the catalytic domain of ST3GalIII, were fused to the MBP amino acid tag.

### Expression of MBP-ST3GalIII in *E. coli* TB1 cells

[0206] The pMAL-ST3GalIII plasmid was transformed into chemically competent *E. coli* TB1 cells. Three isolated colonies containing TB1/pMAL-ST3GalIII construct were picked from the LB agar plates. The colonies were grown in five ml of LB media supplemented

with 60 µg/ml carbenicillin at 37°C with shaking until the liquid cultures reached an OD<sub>620</sub> of 0.7. Two one ml aliquots were withdrawn from each culture and used to inoculate fresh media with or without 500 µM IPTG (final). The cultures were grown at 37°C for two hours. Bacterial cells were harvested by centrifugation. Total cell lysates were prepared heating the cell pellets in the presence of SDS and DTT. IPTG induced expression of MBP-ST3GalIII. (Data not shown.)

#### **Expression of MBP-ST3GalIII and Purification of the inclusion bodies:**

[0207] A one ml aliquot of TB1/pMAL-ST3GalIII overnight culture was inoculated into 0.5 liter of LB media with 50 µg/ml carbenicillin and grown to an OD<sub>620</sub> of 0.7. Expression of MBP-ST3GalIII was induced by addition of 0.5 mM IPTG, followed by overnight incubation at room temperature. The next day bacterial cells were harvested by centrifugation. Cell pellets were resuspended in a buffer containing 75 mM TrisHCl, pH 7.4; 100 mM NaCl; and 1 % glycerol. Bacterial cells were lysed using a French Press. Soluble and insoluble fractions were separated by centrifugation for thirty minutes, 4°C, 10,000 rpm, Sorvall, SS 34 rotor). Soluble and insoluble fractions were separated by centrifugation for thirty minutes at 10,000RPM in a Sorvall, SS 34 rotor at 4°C.

#### **Purification of the inclusion bodies and refolding of MBP-ST3GalIII using GSH/GSSG**

[0208] The MBP-ST3GalIII inclusion bodies were purified and suspended using the same methods and buffers used for the GST-ST3GalIII fusion proteins described above. The MBP-ST3GalIII were refolded using the GSH/GSSG system described above. The refolded MBP-ST3GalIII enzymes were dialyzed against cold 65 mM Tris.HCL pH 7.5, 100 mM NaCl, 1 % glycerol using Pierce SnakeSkin Dialysis bag (MWCO:7 kDa). The refolded and dialyzed MBP-ST3GalIII were concentrated from 3-14 fold using Vivaspin 5 K (VivaScience) concentrators in Jouan centrifuge at 4,000 rpm at 4°C. The refolded MBP-ST3GalIII proteins were analyzed by SDS-Polyacrylamide gel electrophoresis. An 81 kDa MBP-ST3GalIII was detected. (Data not shown.)

#### **MBP-ST3 Gal III enzymatic activity assays**

[0209] Refolded MBP-ST3 Gal III enzymes were assayed for ability to transfer sialic acid from CMP-NAN to LNT-APTS to form LSTd-APTS, as described above. The refolded MBP-ST3 Gal III enzymes were active and transferred sialic acid to LNT-APTS to form LSTd-APTS. (Data not shown.)

[0210] Refolded MBP-ST3 Gal III enzymes were assayed for ability to transfer sialic acid from CMP-NAN to glycoproteins. Transfer of sialic acid to asialo-Transferrin was assayed as described above, for GST-ST3-GalIII enzymes. The refolded MBP-ST3 Gal III enzymes were active and transferred sialic acid to asialo-Transferrin. (Data not shown.)

## 5 Additional assays of conditions for refolding MBP-ST3GalIII

[0211] MBP-ST3GalIII was refolded using the conditions shown in Figure 1. The buffer, redox couple and detergent (if used) were mixed before addition of solubilized IB's to start the refolding reaction. IB's were diluted 1/20. MBP-ST3GalIII refolding was also successful using with different redox couples, for example Cystamine2 HCl/Cysteine at molar ratios of 10  $\frac{1}{4}$ , 4/1, 1/10, or 5/5. (Data not shown.)

## ST3 Gal III enzymatic activity assays

[0212] Refolded MBP-ST3 Gal III enzymes were assayed for ability to transfer sialic acid from CMP-NAN to L<sub>N</sub>T-APTS to form LSTd-APTS, as described above. Results are shown in Figure 1. The highest refolded MBP-ST3 Gal III activities were seen using 15 conditions, 8, 11, 13 and 16. When refolding was scaled up to five ml, MBP-ST3 Gal III proteins refolded using conditions 8 and 16 had the highest activity. (See, *e.g.*, Table 4.)

**Table 4.**

Condition	U/ L folded protein	U/g IB's
8	70	37.0
6	50	40.5

## 25 Purification of MBP-ST3GalIII on amylose column

[0213] Refolded MBP-ST3GalIII proteins from the 5 ml refolding preparation were combined and dialyzed against 100 mM TrisHCl pH 7.4, 100 mM NaCl and 1 % glycerol. The refolded MBP-ST3GalIII proteins were applied to an amylose column. Most of the 30 refolded MBP-ST3GalIII protein was bound to the amylose column and eluted with 10 mM maltose. An elution profile is shown in Figure 2. Enzymatic activity of the MBP-ST3GalIII fractions was determined using the LnNT assay and is shown in Figure 3.

## GlycoPEGylation of asialotransferrin with refolded MBP-ST3GalIII:

[0214] Asialo-transferrin (2 mg/ml) was incubated with purified fractions of refolded 100 35  $\mu$ l of MBP-ST3GalIII in the presence of CMP-SA-PEG (10 kDa, 1.6 mM) or CMP-SA-PEG

(20 kDa, 1.06 mM) in 230  $\mu$ l reaction. GlycoPEGylation reactions were carried out at 30°C overnight or for three days. Aliquots were withdrawn from the reactions and analyzed on 4-20 % SDS-polyacrylamide gel. Results are shown in Figure 4. Purified, refolded MBP-ST3GalIII transfers 10 or 20 K PEGylated sialic acids to asialo-transferrin.

## 5 **Large scale MBP-ST3GalIII refolding**

[0215] The following method was used to make large scale refolded MBP-ST3GalIII.

[0216] Wet IB's (470 mg) were dissolved in IB solubilization Buffer (13 ml) in 15 ml culture tube. IB solubilization buffer includes the following: 4 M Guanidine HCl; 100 mM TrisHCl, pH 9; and 100 mM NaCl. IB's were incubated in IB solubilization buffer at 4°C for about 1  
10 hour with gentle shaking. Any insoluble material was removed by centrifugation in 1.5 mL Eppendorf tubes, at 4°C at max speed, for 30 minutes. The solubilized IB's were transferred to clean tubes and protein concentration was determined using absorbance at 280 nm.

[0217] The following refolding solution was prepared and kept at 4°C: 55 mM MES buffer, pH 6.5; 264 mM NaCl; 11 mM KCl; 0.055 % PEG 550; 550 mM Arginine. The  
15 buffer was supplemented with 0.3 mM Lauryl maltoside (LM); 0.1 mM oxidized glutathione (GSSG); 1 mM reduced glutathione (GSH) immediately before the addition of solubilized IB's. Two ml of solubilized IB's were added into 43 ml of refolding buffer in 50 ml sterile culture tube. The tube was placed on a rocker-shaker and gently shaken for 24 hours at 4°C. The refolded protein was dialyzed in dialysis tubing (MWCO: 7 kD) against Dialysis Buffer  
20 (100 mM Tris HCl, pH 7.5; 100 mM NaCl; and 5 % glycerol) twice (in 10-20 volume excess buffer).

[0218] The large scale dialyzed, refolded MBP-Gal III was analyzed for ST3GalIII activity, and exhibited about 53.6 U/g IB.

### Example 2: Site Directed Mutagenesis of Human GnTI to Enhance Refolding.

25 [0219] A truncated human N-acetylglucosaminyltransferase I was expressed in *E.coli* as a maltose binding fusion protein (GnTI/MBP). The fusion protein was insoluble and was expressed in inclusion bodies. After solubilization and refolding, the GnTI/MBP fusion protein had low activity. The crystal structure of a truncated form of rabbit GnTI (105 amino terminal amino acids deleted) shows an unpaired cysteine residue (CYS123) near the active  
30 site. (See, e.g., Unligil *et al.*, *EMBO J.* 19:5269-5280 (2000)). The corresponding unpaired cysteine in the human GnTI was identified as CYS121 and was replaced with a series of amino acids that are similar in size and chemical characteristics. The amino acids used

include serine (Ser), threonine (Thr), alanine (Ala) and aspartic acid (Asp). In addition, a double mutant, ARG120ALA, CYS121HIS, was also made. The mutant GnTI/MBP fusion proteins were expressed in *E. coli*, refolded and assayed for GnTI activity towards glycoproteins.

5 [0220] Mutagenesis was done using a Quick Change Site-Directed Mutagenesis Kit from Stratagene. Additional restriction sites were introduced with some of the GnT1 mutations. For example an *Apa*I site (underlined, **GGGCCCCAC**) was introduced into the GnT1 ARG120ALA, CYS121HIS mutant, *i.e.*, CGC CTG → **GCC CAC** (changes in bold). The following mutagenic oligonucleotides were used to make the double mutant: GnT1 R120A, 10 C121H+, 5'CCGCAGCACTGTTCTGGG**CCCCAC**CTGGACAAGCTGCTG 3'; and GnT1 R120A, C121H- 5'CAGCAGCTTGTCCAG**GTGGGCCCCGA**ACAGTGCTGCGG 3' (changes shown in bold). An *Asc*I site (underlined, **GGCGCGCC**) was introduced into the GnT1 CYS121ALA mutant, *i.e.*, CTG → **GCC** (changes in bold). The following mutagenic oligonucleotides were used to make the GnT1 CYS121ALA mutant: GnT1C123A+ 15 5'AGCACTGTTCTGGCG**CGCC**CTGGACAAGCTGCTG 3; and GnT1C123A- 5'CAGCAGCTTGTCCAG**GGCGCGCCGA**ACAGTGCT 3'

[0221] The activity of the mutant proteins expressed in *E. coli* was compared to the activity of wild type GnT1 expressed in baculovirus. A CYS121SER GNTI mutant was active in a TLC based assay. In contrast, a CYS121THR mutant had no detectable activity and a 20 CYS121ASP mutant had low activity. A CYS121ALA mutant was very active, and a double mutant, ARG120ALA, CYS121HIS, based on the amino acid sequence of the *C. elegans* GnT1 protein (Gly14), also exhibited activity, including transfer of GlcNAc to glycoproteins. Amino acid and encoding nucleic acid sequences of the GnT1 mutants are provided in Figures 7-11.

### 25 Example 3: One Pot Method of Refolding Multiple Glycosyltransferases.

[0222] Eukaryotic ST3GalIII, GalT1, and GnT1 enzymes build N-glycan chains on glycoproteins. Additional modifications, for example GlycoPEGylation, can be performed using CMP-NAN-PEG as a donor substrate. Eukaryotic ST3GalIII, GalT1, and GnT1 enzymes are typically expressed in eukaryotic expression systems, for example fungal or 30 mammalian cells.

[0223] Eukaryotic ST3GalIII, GalT1, and GnT1 enzymes each fused to a maltose binding protein (MBP) domain were solubilized, combined, and refolded together in a single vessel.

The MBP fused and refolded enzymes were active and were used to add N-glycans to glycoproteins or to glycoPEGylate glycoproteins. The refolding buffer included a redox couple, for example, glutathione oxidized/reduced (GSH/GSSG). Refolding was enhanced by addition of arginine and polyethylene glycol 3350 (PEG). The IB's can be solubilized individually and added to refolding buffer in different proportions or solubilized together from IB's and added to the refolding buffer directly. The one step purification or immobilization of these enzymes can also be done using the MBP fusion tag.

*Preparation of a refolded glycosyltransferase mixture (SuperGlycoMix)*

**Preparation of the glycosyltransferases IB's**

**[0224]** Bacterial strains used to produce eukaryotic ST3GalIII, GalT1, and GnT1 enzymes are shown in Table 5. The table also shows the estimated molecular weight of the MBP fusion proteins. (MW based on amino acid composition, Vector NTI software.) All nucleic acids encoding the eukaryotic enzymes were expressed from IPTG inducible expression vectors.

**Table 5**

Strain/Construct	Protein expressed (IBS's)	MW (kD)
JM109/pCWori-MBP-GaT1 ( $\Delta$ 129) C342T	MBP-GalT1( $\Delta$ 129) C342T	74.2
JM109/pCWIN2-MBP-GnT1 ( $\Delta$ 103) C121A	MBP-GnT1( $\Delta$ 103) C121A	82.4
TB1/pMAL-ST3GalIII	MBP-ST3GalIII	82

**[0225]** Following IPTG induction of *E. coli* cultures, IB's containing GnT1, GalT1 and ST3GalIII enzymes isolated by lysing the cells using a French Press or detergent lysis (Novagen's Bugbuster Reagent). Pellets were recovered after centrifugation and processed to obtain IB's, as described previously. IB's were washed at least two times using Novagen's IB wash buffer. Washed IB's were stored at -20°C until they are ready to use in refolding experiments

**[0226]** IB's containing ST3GalIII, GalT1, or GnT1 were separately dissolved in a buffer containing 6 M Guanidine HCl, 50 mM TrisHCl pH 8.0, 5 mM EDTA, 10 mM DTT at 4°C for one hour. Cleared supernatants were obtained after centrifugation (Max speed at Eppendorf Micro-centrifuge). The protein content of the solubilized IB's was determined by measuring absorbance at 280 nm. The protein contents in Table 6 were determined based on



the extinction coefficients of each MBP-Glycosyltransferase. The extinction coefficients were calculated using Vector NTi software (See Table 5)

**Table 6.** Protein concentrations in solubilized IB's.

5	<u>Protein</u>	<u>A280 at 1 mg/ml</u>	<u>mg/ml</u>
	MBP-ST3GalIII	1.49	4.23
	MBP-GalT1( $\Delta$ 129) C342T	1.39	6.80
10	MBP-GnT1( $\Delta$ 103) C121A	1.7	3.29

### One pot refolding of Glycosyltransferases

15 [0227] Solubilized IB's were mixed at equal amounts, as shown in Table 7.

**Table 7.** Solubilized IB's were mixed at following amounts before refolding.

	<u>Protein</u>	<u>V(mL)</u>	<u>mg</u>	<u>% of total protein</u>
	MBP-ST3GalIII	0.8	3.4	36
20	MBP-GalT1( $\Delta$ 129) C342T	0.5	3.4	36
	MBP-GnT1( $\Delta$ 103) C121A	0.8	2.6	28
25	Total	2.1	9.4	100

[0228] The protein concentration of the total solubilized IB mixture was 4.5 mg/ml. The mixture was diluted approximately 1/20 in refolding buffer making the final concentration of the total protein mixture 0.22 mg/mL. Refolding buffer containing 55 mM MES, pH 6.5; 550 mM Arginine; 0.055 % PEG3350; 264 mM NaCl; 11 mM KCl; 1 mM GSH; and 0.1 mM GSSG. Refolding can also be performed in a buffer with Tris HCl, pH 8.2 and a Cysteine/Cystamine redox couple can be substituted for GSH/GSSG. The IB mixture was diluted into the refolding buffer and incubated at 4°C overnight (16-18 hours). Estimated concentrations of the glycosyltransferases in refolding reaction:

MBP-ST3GalIII	0.081 mg/mL
MBP- GalT1 ( $\Delta$ 129) C342T	0.081 mg/mL
MBP-GnT1 ( $\Delta$ 103) C121A	0.062 mg/mL

40 [0229] After overnight refolding, the refolded glycosyltransferase mix was dialyzed to remove chaotropic agent (*i.e.* Guanidine HCl). Dialysis was carried out twice against 50 mM

TrisHCl pH 8.0 at 4°C (20 fold per dialysis) in a dialysis bag (SnakeSkin, MWCO: 7 kD, Pierce). The dialyzed refolded glycosyltransferase mix (Superglycomix, SGM) was concentrated six fold using VivaSpin 6 mL (MWCO: 10 kD) centrifugal concentrators. After concentration, all three glycoproteins were present in the mixture, as determined by SDS-PAGE analysis. (Data not shown.) After concentrating the SGM, enzymatic activities of GnT1, GalT1, and ST3GalIII were determined.

#### *Enzymatic activities of SuperGlycoMix*

[0230] Superglycomix (SGM), the one pot refolded glycosyltransferase mix contains three glycosyltransferases: ST3GalIII, GalT1 and GnT1. These enzymes were individually assayed for their enzymatic activities and analyzed using the methods indicated below. The enzymatic activities are listed in Table 8.

#### **ST3 Gal III enzymatic activity assays**

[0231] ST3GalIII assays were carried out using HPLC/UV (High Performance Liquid Chromatography with Ultraviolet Detection). The conversion of LNnT (Lacto-*N*-Neotetraose) into LSTd (Lactosialic-Tetrasaccharide-d) using CMP-NAN (cytidine 5'-Monophosphate- $\beta$ -D-sialic acid) by ST3GalIII enzyme was performed as follows. The reaction was carried out in a 96 well microtiter plate in 100  $\mu$ l of 20 mM MOPS, pH 6.5 buffer containing 2 mM CMP-NAN, 30 mM LNnT, 10 mM MnCl<sub>2</sub> and 20  $\mu$ l of refolded enzyme at 30°C for 120 minutes. The reaction was quenched by heating to 98°C for 1 min. The microtiter plate was centrifuged at 3600 rpm for 10 min to pellet any precipitate. 75  $\mu$ l of supernatant was diluted 1:1 with 75  $\mu$ l of water. The diluted reaction was analyzed by LC/UV using a YMC-Pack Polyamine II column with a sodium phosphate buffer/acetonitrile gradient and detection at 200 nm. The sample product peak area was compared to an LSTd calibration curve, and the activity was calculated based on the amount of LSTd produced per min per  $\mu$ l of enzyme in the reaction.

#### **GalTI enzymatic activity assays:**

[0232] The enzymatic assays were carried out using HPLC/PAD (High Performance Liquid Chromatography with Pulsed Amperometric Detection). The conversion of LNT2 (Lacto-*N*-Triose-2) into LNnT (Lacto-*N*-Neotetraose) using UDP-Gal (Uridine 5'-Diphosphogalactose) by GalTI enzyme was performed as follows. The reaction was carried out in 100  $\mu$ l of 50 mM Hepes, pH 7 buffer containing 6 mM UDP-Gal, 5 mM LNT-2, 5 mM MnCl<sub>2</sub> and 100  $\mu$ l of refolded enzyme at 37°C for 60 minutes. The reaction was quenched (1 to 10 dilution)

with water and centrifuged through a 10,000 MWCO spin filter. The filtrate was then diluted 1 to 10. This diluted reaction was analyzed by HPLC using a Dionex DX-500 system and a CarboPac PA1 column with sodium hydroxide buffer. The sample product peak area was compared to an LNnT calibration curve, and the activity was calculated based on the amount of LNnT produced per min per  $\mu\text{l}$  of enzyme in the reaction.

#### **GnTI enzymatic activity assays:**

**[0233]** The activity of GnTI is determined by measuring the transfer of a tritiated sugar from UDP- $^3\text{H}$ -GlcNAc (Uridine diphosphate N-acetyl-D-glucosamine [ $6\text{-}^3\text{H}(\text{N})$ ]) to n-octyl 3,6-Di-O-( $\alpha$ -mannopyranosyl)  $\beta$ -D-mannopyranoside (OM3), a trimannosyl core with an octyl tail. The reaction was carried out in 20  $\mu\text{l}$  of 100 mM MES, pH 6.0 buffer containing 3 mM UDP-GlcNAc, 0.1 mM UDP- $^3\text{H}$ -GlcNAc, 0.5 mM OM3, 20 mM  $\text{MnCl}_2$  and 10  $\mu\text{l}$  of refolded enzyme at 37°C for 60 minutes. The reaction was quenched (1 to 6 dilution) with water and applied to a polymeric reversed-phase resin in a 96 well format that was previously conditioned according to the manufacturer's recommendations. The resin was washed twice with 200  $\mu\text{l}$  of water and the product was eluted with 50  $\mu\text{l}$  of 100% MeOH into a capture plate. Scintillation fluid (200  $\mu\text{L}$ ) was added to each well and the plate was mixed and counted using a PerkinElmer TopCount NXT microplate scintillation counter. The activity was calculated based on the amount of  $^3\text{H}$ -GlcNAc incorporated into the product per min per  $\mu\text{l}$  of enzyme in the reaction.

**Table 8.** Enzymatic activities of refolded Glycosyltransferases in SGM

Enzymatic activity	mU/mL
GnT1	1
GalT1	165
ST3GalIII	10

**[0234]** The activities reported in the table above are close or in the range when these enzymes were refolded separately. GnT1 and GalT1 activities are close to those obtained using mammalian or baculovirus expression systems. ST3GalIII activities are somewhat lower than in ST3GalIII preparation obtained after fungal expression system. The ST3GalIII assay used here is modified from the procedure and values reported here approximately 4-5 fold lower than those obtained a method based on CE-LIF (Capillary electrophoresis-Laser induced Fluorescence).

### Remodeling RNaseB-Man<sub>5</sub> using Superglycomix

[0235] A small glycoprotein, RNaseB with one N linked Man<sub>5</sub> sugar, was remodeled by SGM in the presence of UDP-sugars (UDP-GlcNAc and UDP-Gal). The remodeling reaction was carried out either using UDP-GlcNAc or both UDP-GlcNAc and UDP-Gal to test the both GnT1 and GalT1 activities. Eight µl of SGM was added to 10 mM MES buffer pH 6.5 containing 5 mM UDP-GlcNAc, or/and 5 mM UDP-Gal, 9 µg RNaseBMan<sub>5</sub>, 5 mM MnCl<sub>2</sub> in 25 µl assay incubated at 33°C for overnight to 48 hours. At the end of the reaction, ten µl aliquots were dialyzed against H<sub>2</sub>O and 1.5 µl samples were spotted on MALDI-TOF plates. Samples were analyzed on MALDI-TOF after being treated with TFA and cinnapinic acid.

[0236] The remodeling of RNaseBman<sub>5</sub> was done by transferring GlcNAc and Gal on Man<sub>5</sub> of the RNaseB. After 48 hrs incubation at 33°C, majority of the GlcNAc and Gal transfer onto RNaseB was accomplished as indicated in MALDI-TOF spectra of the remodeled RNaseBMan<sub>5</sub>. Results are summarized in Table 9.

**Table 9.** MALDI-TOF Spectra of the species after SGM reactions.

m/z			
RNaseB			
Reaction	Man <sub>5</sub>	Man <sub>5</sub> -GlcNAc	Man <sub>5</sub> GlcNAc-Gal
No Enzyme	14983	-	-
SGM+ UDP-GlcNAc	14973	15177	-
SGM+ UDP-GlcNAc +UDP-Gal	14982	15170	15348

### GlycoPEGylation EPO remodeling using SGM

[0237] GlycoPEGylation (20 K) was carried out in one pot reaction composed of the following components: 10 mM MES pH 6.5, 5 mM MgCL<sub>2</sub>, 5 mM UDP-GlcNAc, 5 mM UDP-GalNAc, 0.5 mM CMP- SA-PEG (20 kDa), 24 µg EPO, 8 µL concentrated SGM. In control reactions, SGM was replaced by individual enzymes either refolded or expressed in mammalian cells or insect cells or *Aspergillus*. After overnight incubations, the reactions were analyzed on SDS-polyacrylamide gel. Results are shown in Figure 5. SGM added 20K PEG to EPO.

*Assessment of one pot refolding conditions for multiple glycosyltransferases*

**[0238]** Conditions for refolding multiple glycosyltransferases were assessed, including pH and refolding two or three enzymes at once.

**Preparation of glycosyltransferase inclusion bodies**

5 **[0239]** *E. coli* strains transformed with glycosyltransferase expression plasmids were described previously, with one exception. MBP-ST3GalIII was expressed in JM109 cells from a pCWori-ST3GalIII plasmid. The inclusion bodies were isolated and solubilized as described above. Protein contents were assessed as described above and are shown in Table 10.

10 **Table 10.** Solubilized IB's were mixed at following amounts before refolding.

	<b>Protein</b>	<b>A280</b>	<b>A280 (at 1 mg/ml)</b>	<b>mg</b>	<b>% (of sol. protein)</b>
	MBP-ST3GalIII	32.3	1.49	21.7	13.6
	MBP-GalT1( $\Delta$ 129) C342T	35.7	1.39	25.7	13.7
15	MBP-GnT1( $\Delta$ 103) C121S	42.8	1.7	25.2	9.7

**One pot refolding of Glycosyltransferase IB mixtures**

**[0240]** After determining their protein contents, solubilized IB's were mixed at amounts shown before diluted in the refolding buffers (Table 11). Refolding experiments of the GT's  
20 were carried out in 44 ml volume at 4°C at stationary phase using buffer A or B (below) and 0.1 mM GSSG and 1 mM GSH. **Buffer A:** 55 mM MES pH 6.5, 550 mM Arginine, 0.055 % PEG3350, 264 mM NaCl, 11 mM KCl, supplemented with 1 mM GSH, 0.1 mM GSSG.  
**Buffer B:** 55 mM TrisHCl pH 8, 550 mM Arginine, 0.055 % PEG3350, 264 mM NaCl, 11 mM KCl, supplemented with 1 mM GSH, 0.1 mM GSSG.

25

**Table 11. Mixing amounts of solubilized GT IB's in 2 mL IBSB****Refolding in Buffer A**

<b>Refold 1 (A-2x)</b>		<b>Conc(mg/mL)</b>	<b>V (mL)</b>	<b>mg</b>
5	MBP-GnT1 ( $\Delta$ 103) C121S	25.2	0.2	5
	MBP- GalT1 ( $\Delta$ 129) C342T	25.7	0.2	5
	IBSB	-	1.6	-
<b>Refold 2 (A-3x)</b>		<b>Conc(mg/mL)</b>	<b>V (mL)</b>	<b>mg</b>
10	MBP-GnT1 ( $\Delta$ 103) C121S	25.2	0.2	5
	MBP- GalT1 ( $\Delta$ 129) C342T	25.7	0.2	5
	MBP-ST3GalIII	21.7	0.4	8.7
	IBSB	-	1.2	-

**Refolding in Buffer B**

<b>Refold 3 (B-2x)</b>		<b>Conc(mg/mL)</b>	<b>V (mL)</b>	<b>mg</b>
15	MBP-GnT1 ( $\Delta$ 103) C121S	25.2	0.2	5
	MBP- GalT1 ( $\Delta$ 129) C342T	25.7	0.2	5
	IBSB	-	1.4	-
<b>Refold 4 (B-3x)</b>		<b>Conc(mg/mL)</b>	<b>V (mL)</b>	<b>mg</b>
20	MBP-GnT1 ( $\Delta$ 103) C121S	25.2	0.2	5
	MBP- GalT1 ( $\Delta$ 129) C342T	25.7	0.2	5
	MBP-ST3GalIII	21.7	0.4	8.7
	IBSB	-	1.2	-

**[0241]** For double refolding (2x, two glycosyltransferases) 10 mg total protein in 2 ml was added into 41 mL refolding buffer (above) 0.45 mL 100 mM GSH, 0.45 mL 10 mM GSSG, after dilution total protein was 0.44 mg/ml. For triple refolding (3x, three glycosyltransferases) 18.7 mg total protein in 2 ml was added into 41 mL refolding buffer (above), 0.45 mL 100 mM GSH, 0.45 mL 10 mM GSSG. After dilution total protein was 0.83 mg/ml. The protein concentrations were higher than previous triple refolding experiment (0.22 mg/ml in SGM). Estimated concentrations of the glycosyltransferases in refolding reaction follow:

35	MBP-ST3GalIII	0.39 mg/mL
	MBP- GalT1 ( $\Delta$ 129) C342T	0.23 mg/mL
	MBP-GnT1 ( $\Delta$ 103) C121S	0.23 mg/mL

**[0242]** After overnight refolding, the refolded glycosyltransferase mix was dialyzed. Dialysis was carried out twice against 50 mM TrisHCl pH 8.0 at 4°C in a dialysis bag

(SnakeSkin, MWCO: 7 kD, Pierce). After dialysis, the glycosyltransferase mix was concentrated 9-12 fold using 6 mL VIVA-Spin (MWCO: 10 K) centrifugal concentrators.

[0243] SDS-PAGE analysis demonstrated that the proteins were present after refolding, dialysis, and concentration.

## 5 Enzymatic assays of refolded glycosyltransferase mixtures

[0244] Enzymatic assays were performed as described above. Results are shown in Table 12.

**Table 12.** Enzymatic activities of refolded Glycosyltransferases after double and triple refolding experiments.

Folding	Fold conc	Enzymatic activity	mU/mL
Buffer A (A-2x)		GnT1 GalT1	0.84 598
Buffer A (A-3x)		GnT1 GalT1 ST3GalIII	0.16 306 4
Buffer B (B-2x)		GnT1 GalT1	3.32 747
Buffer B (B-3x)		GnT1 GalT1 ST3GalIII	0.47 425 11

[0245] The highest activity was seen on mixing MBP fused GnT1 and GalT1 in equal amounts and refolded in buffer B. Adding non-equivalent amount of MBP-fused ST3GalIII affected refolding efficiency due to total high protein. Nevertheless, two different refolding buffer using either two GT's or three GT's, can be used to obtain active soluble proteins.

[0246] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

WHAT IS CLAIMED IS:

- 1                   1.       A recombinant eukaryotic N-acetylglucosaminyltransferase I (GnTI)  
2 enzyme, comprising the catalytic domain of the GnTI enzyme;  
3                   wherein an unpaired cysteine residue is mutated, and  
4                   wherein the GnTI enzyme catalyzes the transfer of a donor substrate to an  
5 acceptor substrate.
- 1                   2.       The GnTI enzyme of claim 1, wherein the vertebrate GnTI enzyme is  
2 human.
- 1                   3.       The GnTI enzyme of claim 2, comprising a CYS121 mutation,  
2                   wherein the CYS121 mutation is a member of the group consisting of a  
3 CYS121SER mutation, a CYS121ALA mutation, and a CYS121ASP mutation.
- 1                   4.       The GnTI enzyme of claim 2, comprising an ARG120ALA,  
2 CYS121HIS mutant.
- 1                   5.       The GnTI enzyme of claim 1, wherein the GnTI enzyme further  
2 comprises an amino acid tag.
- 1                   6.       The GnTI enzyme of claim 5, wherein the amino acid tag is selected  
2 from the group consisting of a maltose binding protein (MBP), a polyhistidine tag, a  
3 glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope.
- 1                   7.       The GnTI enzyme of claim 1, wherein the GnTI enzyme comprises an  
2 amino acid sequence from figures 7-11.
- 1                   8.       The GnTI enzyme of claim 7, further comprising a maltose binding  
2 domain.
- 1                   9.       An isolated polynucleotide, the polynucleotide comprising a nucleic  
2 acid sequence that encodes a eukaryotic N-acetylglucosaminyltransferase I (GnTI) enzyme  
3 comprising a catalytic domain of the GnTI enzyme,  
4                   wherein an unpaired cysteine residue is mutated, and  
5                   wherein the GnTI enzyme catalyzes the transfer of a donor substrate to an  
6 acceptor substrate.



- 1                    10.     The GnTI enzyme of claim 9, wherein the GnTI enzyme is a human  
2 protein.
- 1                    11.     The isolated polynucleotide of claim 10, wherein the GnTI enzyme  
2 comprises a CYS121 mutation,  
3                    wherein the CYS121 mutation is a member of the group consisting of a  
4 CYS121SER mutation, a CYS121ALA mutation, and a CYS121ASP mutation.
- 1                    12.     The isolated polynucleotide of claim 11, comprising an ARG120ALA,  
2 CYS121HIS mutant.
- 1                    13.     The isolated polynucleotide of claim 9, wherein the GnTI enzyme  
2 further comprises an amino acid tag.
- 1                    14.     The GnTI enzyme of claim 13, wherein the amino acid tag is selected  
2 from the group consisting of a maltose binding protein (MBP), a polyhistidine tag, a  
3 glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope.
- 1                    15.     The isolated polynucleotide of claim 9, wherein the GnTI enzyme  
2 comprises an amino acid sequence from Figures 7-11.
- 1                    16.     An expression vector comprising the isolated polynucleotide of claim  
2 9.
- 1                    17.     A host cell comprising the expression vector of claim 16.
- 1                    18.     A method of producing a eukaryotic N-acetylglucosaminyltransferase I  
2 (GnTI) enzyme, the method comprising culturing a host cell of claim 17 under conditions  
3 suitable for the production of the GnTI enzyme.
- 1                    19.     A method of adding an N-acetylglucosamine residue to an acceptor  
2 molecule comprising a terminal mannose residue, the method comprising contacting the  
3 acceptor molecule with an activated N-acetylglucosamine molecule and a eukaryotic N-  
4 acetylglucosaminyltransferase I (GnTI) enzyme of claim 1.
- 1                    20.     The method of claim 19, wherein the acceptor molecule is a  
2 glycoprotein.

- 1                    21.     A method of refolding at least two insoluble, recombinant eukaryotic  
2 glycosyltransferase proteins in a single vessel, the method comprising  
3                    contacting the glycosyltransferases with a refolding buffer under conditions  
4 suitable for refolding the enzymes, wherein the refolding buffer comprises a buffer and a  
5 redox couple, and wherein the refolded glycosyltransferases has biological activity.
- 1                    22.     The method of claim 21, wherein the refolding buffer further  
2 comprises arginine.
- 1                    23.     The method of claim 21, wherein the refolding buffer further  
2 comprises PEG.
- 1                    24.     The method of claim 21, wherein the glycosyltransferases further  
2 comprise an amino acid tag.
- 1                    25.     The method of claim 24, wherein the amino acid tag is a member  
2 selected from the group consisting of a maltose binding protein (MBP), a polyhistidine tag, a  
3 glutathione S transferase (GST), a starch binding protein (SBP), and a myc epitope
- 1                    26.     The method of claim 21, wherein the glycosyltransferases are part of  
2 an N-linked glycan biosynthetic pathway.
- 1                    27.     The method of claim 26, wherein a first glycosyltransferase is a  
2 sialyltransferase.
- 1                    28.     The method of claim 26, wherein a first glycosyltransferase is an N-  
2 acetylglucosaminyltransferase.
- 1                    29.     The method of claim 26, wherein a first glycosyltransferase is a  
2 galactosyltransferase.
- 1                    30.     The method of claim 26, wherein a first glycosyltransferase is a  
2 sialyltransferase, a second glycosyltransferase is an N-acetylglucosaminyltransferase, and a  
3 third glycosyltransferase is a galactosyltransferase.
- 1                    31.     The method of claim 21, wherein the glycosyltransferases are part of  
2 an O-linked glycan biosynthetic pathway

- 1                    32.     A reaction mixture for producing an oligosaccharide, the reaction  
2 mixture comprising at least two glycosyltransferases that have been refolded in the same  
3 vessel, wherein a first glycosyltransferase is a eukaryotic N-acetylglucosaminyltransferase I  
4 (GnTI) enzyme of claim 1.
- 1                    33.     The reaction mixture of claim 32, wherein a second glycosyltransferase  
2 is a sialyltransferase.
- 1                    34.     The reaction mixture of claim 32, wherein a second glycosyltransferase  
2 is a galactosyltransferase.
- 1                    35.     The reaction mixture of claim 32, wherein a second glycosyltransferase  
2 is a sialyltransferase, and a third glycosyltransferase is a galactosyltransferase.
- 1                    36.     A method of producing an oligosaccharide, the comprising contacting  
2 an acceptor molecule with a donor sugar, and a reaction mixture of claim 32.
- 1                    37.     A method of refolding an insoluble recombinant eukaryotic  
2 sialyltransferase, the method comprising the steps of:  
3                    (a) solubilizing the sialyltransferase; and  
4                    (b) contacting the soluble sialyltransferase with a buffer comprising a redox  
5 couple to refold the sialyltransferase, wherein the refolded sialyltransferase catalyzes the  
6 transfer of sialic acid from a donor substrate to an acceptor substrate.
- 1                    38.     The method of claim 37, further comprising the step of dialyzing or  
2 diafiltering the refolded sialyltransferase.
- 1                    39.     The method of claim 37, wherein the buffer further comprises a  
2 detergent.
- 1                    40.     The method of claim 37, wherein the buffer further comprises a  
2 chaotropic agent.
- 1                    41.     The method of claim 37, wherein the buffer further comprises arginine.
- 1                    42.     The method of claim 37, wherein the buffer pH is between 6.0 and  
2 10.0.

- 1                    43.     The method of claim 42, wherein the buffer pH is between 6.5 and 8.0.
- 1                    44     The method of claim 42, wherein the buffer pH is between 8.0 and 9.0.
- 1                    45.     The method of claim 37, wherein the sialyltransferase comprises an  
2 amino acid tag.
- 1                    46.     The method of claim 45, wherein the amino acid tag is selected from  
2 the group consisting of a maltose binding protein (MBP), a polyhistidine tag, a glutathione S  
3 transferase (GST), a starch binding protein (SBP), and a myc epitope.
- 1                    47.     The method of claim 45, further comprising the step of purifying the  
2 sialyltransferase using a tag binding molecule.
- 1                    48.     The method of claim 47, wherein the amino acid tag is MBP and the  
2 tag binding molecule is amylose, maltose, or a cyclodextrin.
- 1                    49.     The method of claim 37, wherein the refolded sialyltransferase  
2 catalyzes the transfer of sialic acid from CMP-sialic acid to a glycoprotein.
- 1                    50.     The method of claim 37, wherein the refolded sialyltransferase  
2 catalyzes the transfer of 10KPEG or 20K PEG from CMP-SA-PEG (10 kDa) or CMP-SA-  
3 PEG (20 kDa)to a glycoprotein.
- 1                    51.     The method of claim 37, wherein the sialyltransferase is rat liver  
2 ST3GalIII.
- 1                    52.     The method of claim 51, wherein the recombinant mammalian  
2 sialyltransferase comprises a maltose binding protein (MBP) amino acid tag.
- 1                    53.     The method of claim 52, further comprising the step of purifying the  
2 refolded mammalian sialyltransferase using a tag binding molecule selected from the group  
3 consisting of amylose, maltose, or a cyclodextrin.
- 1                    54.     The method of claim 51, wherein the redox couple is reduced  
2 glutathione/oxidized glutathione (GSH/GSSG).

1                    55.     The method of claim 54, wherein the molar ratio of GSH/GSSG is  
2     between 100:1 and 1:10.

1                    56.     The method of claim 51, wherein the buffer comprises about 0.02-10  
2     mM GSH, 0.005-10 mM GSSG, 0.005-10 mM lauryl maltoside, 50-250 mM NaCl, 2-10 mM  
3     KCl, 0.01-0.05% PEG 3350, and 150-550 mM L-arginine.

1                    57.     A method of adding a sialyl moiety to a glycoprotein, the method  
2     comprising contacting the glycoprotein with CMP-sialic acid and a refolded mammalian  
3     sialyltransferase of claim 37.

1                    58.     A method of adding a PEG moiety to a glycoprotein, the method  
2     comprising contacting the glycoprotein with CMP-10KPEG or CMP-20KPEG and a refolded  
3     mammalian sialyltransferase of claim 37.

**METHODS OF REFOLDING MAMMALIAN  
GLYCOSYLTRANSFERASES**

**ABSTRACT OF THE DISCLOSURE**

The present invention provides methods of refolding mammalian glycosyltransferases that have been produced in bacterial cells, and methods to use such refolded glycosyltransferases, including glycosyltransferase mutants that have enhanced ability to be refolded. The invention also provides methods of refolding more than one glycosyltransferase in a single vessel, methods to use such refolded glycosyltransferases, and reaction mixtures comprising the refolded glycosyltransferases.

11474739 v1

#	1 mM	0.1 mM	0.3 mM	mM	mM	0.055%	550 mM	1.1 mM	2.2 mM	2.2 mM	440 mM	550 mM	Activity
	GSH	GSSG	LM	NaCl	KCl	PEG 3350	GndHCl	EDTA	MgCl <sub>2</sub>	CaCl <sub>2</sub>	Sucrose	L-Arg	U/g IB
2 (55 mM MES pH 6.5)	+	+	+	10.56	0.44	0	+	0	+	+	0	0	0
3 (55 mM MES pH 6.5)	+	+	0	10.56	0.44	+	+	+	0	0	+	+	0
#5 (55 mM MES pH 6.5)	+	+	0	264	11	0	0	0	+	+	+	0	0
#8 (55 mM MES pH 6.5)	+	+	+	264	11	+	0	+	0	0	0	+	40.00
#10 (55 mM Tris pH 8.2)	+	+	+	10.56	0.44	0	0	+	0	0	+	0	0
#11 (55 mM Tris pH 8.2)	+	+	0	10.56	0.44	+	0	0	+	+	0	+	105.26
#13 (55 mM Tris pH 8.2)	+	+	0	264	11	0	+	+	0	0	0	0	15.65
#16 (55 mM Tris pH 8.2)	+	+	+	264	11	+	+	0	+	+	+	+	48.70

Figure 1




Figure 2



**ST3 Gal III activities of the Amylose purified  
refolded MBP-ST3Gal III fractions**




Figure 3





Figure 4



**Figure 5. GlycoPEGylation (20 K) of EPO**

**Figure 5**

```

      10      20      30      40      50      60
/usr/t MLKKQSAGLVWGAIFVAWNALLLFFWTRPAPGRPPSVSALDGD PASLTREVIRLAQD
      .....
P27115 MLKKQSAGLVWGAIFVAWNALLLFFWTRPVPSRLPSDNALDDDPASLTREVIRLAQD
      10      20      30      40      50      60

      70      80      90      100     110
/usr/t AEVELERQRGLLQQIGD--ALSSQGRVPTAAPPAQPRVPVTPAPAVIPILVIACDRSTV
      .....
P27115 AEVELERQRGLLQQIREHHALWSQRWKVPTAAPPAQPHVPVTPPPAVIPILVIACDRSTV
      70      80      90      100     110     120

      120     130     140     150     160     170
/usr/t RRCLDKLLHYRPSAELFPIIVSQDCGHEETAQAIASYSYSAVTHIRQPDLSIAVPPDHRK
      .....
P27115 RRCLDKLLHYRPSAELFPIIVSQDCGHEETAQVIASYSYSAVTHIRQPDLSNIAVQPDHRK
      130     140     150     160     170     180

      180     190     200     210     220     230
/usr/t FQGYKIIARHYRWALGQVFRQFRPAAVVVEDDLEVAPDFFEYFRATYPLLKADPSLWCV
      .....
P27115 FQGYKIIARHYRWALGQIFHNFNYPAAVVVEDDLEVAPDFFEYFQATYPLLKADPSLWCV
      190     200     210     220     230     240

      240     250     260     270     280     290
/usr/t SAWNDNGKEQMVDASRPPELLYRTDFFPGLGWLLLAELWAELEPKWPKAFWDDWMRRPEQR
      .....
P27115 SAWNDNGKEQMVDSSKPELLYRTDFFPGLGWLLLAELWAELEPKWPKAFWDDWMRRPEQR
      250     260     270     280     290     300

      300     310     320     330     340     350
/usr/t QGRACIRPEISRTMTFGRKGVSHGQFFDQHLKFIKLNQQFVHFTQLDLSYLQREAYDRDF
      .....
P27115 KGRACVRPEISRTMTFGRKGVSHGQFFDQHLKFIKLNQQFVPFTQLDLSYLQREAYDRDF
      310     320     330     340     350     360

      360     370     380     390     400     410
/usr/t LARVYGAPQLQVEKVRTNDRKELGEVRVQYTGRDSFKAFKALGVMDDLKSGVPRAGYRG
      .....
P27115 LARVYGAPQLQVEKVRTNDRKELGEVRVQYTGRDSFKAFKALGVMDDLKSGVPRAGYRG
      370     380     390     400     410     420

      420     430     440
/usr/t IVTFQFRGRRVHLAPPPTWEGYDPSWN
      .....
P27115 IVTFLFRGRRVHLAPPQTWDGYDPSWT
      430     440

```

Figure 6

## GnT1 Cys121Ser mutant

avipilviacdrstvrrsldklhlhyrpsaelfpaiivsqdcgheetaqaiasygsavthirqpdlssiavppdhrkfqqgyykiarhyrwa  
lgqvfrqfrfpaavvveddlevapdffeyfratypllkadpslwcvswndngkeqmvdasrpellyrtdffpglgwllaelwae  
lepkwpkafwddwmrrpeqrqgracirpeisrtmtfgrkgvshgqffdqhlkfiklnqqfvhftqldlsylqreaydrdflarvyg  
apqlqvekvrtndrkelgevrvytgrdsfkafakalgvmddlksgvpragyrgivtfqfgrrvhlappptwegydpwn\*

Gcgggtattcccatcctgggtatcgcctgtgaccgcagcactgttcggcgctctctagacaagctgctgcattatcgccctcggtga  
gctcttcccatcatcgttagccaggactgcgggcacgaggagacggcccaggccatcgctcctacggcagcgcggtcacgcaca  
tccggcagcccagctgagcagcattcggtgccgccggaccaccgcaagttccagggtactacaagatcgcgcgccactaccg  
ctgggcgctgggccaggtcttccggcagtttcgcttccccgcggccgtggtggtggaggatgacctggaggtggccccggacttctt  
cgagtactttcgggccacctatcgctgctgaaggccgaccttccctgtggtgcgtctcggcctggaatgacaacggcaaggagca  
gatggtggacgccagcaggcctgagctgctctaccgcaccgacttttccctggcctgggctggctgctgttggccgagctctgggct  
gagctggagcccaagtggccaaaggccttctgggacgactggatgcggcgccggagcagcggcaggggcgggcctgcatacg  
ccctgagatctcaagaacgatgaccttggccgaagggtgtgagccacgggcagttcttgaccagcacctcaagttatcaagctga  
accagcagtttgtgcacttcaccagctggacctgtcttacctgcagcgggaggcctatgaccgagatttctcggccgcgtctacggt  
gtccccagctgcaggtggagaaagtgaggaccaatgaccggaaggagctgggggaggtgcgggtgcagtatacgggcaggga  
cagcttcaaggcttcccaaggctctgggtgtcatggatgaccttaagtcgggggttccgagagctggctaccggggtattgtcacctt  
ccagttccggggccgccgtgtccacctggcgccccaccgacgtgggagggctatgatcctagctggaattag

Figure 7

## GnT1 Cys121Asp

avipilviacdrstvrrdldkllhyrpsaelfpilvsqdcgheetaqaiasygsavthirqpdlssiavppdhrkfqgyykiarhyrwa  
lgqvfrqfrfpaavvveddle vapdffeyfratypllkadpslwcv sawndngkeqmvdasrpellyrtdffpglgwllaelwae  
lepkwpkafwddwmrrpeqrqgracirpeisrtmtfgrkgvshgqffdqhlkfiklnqqfvhftqlldsylqreaydrdflarvyg  
apqlqvekvrtndrkelgevrqvtytgrdsfkafakalgvmddlksgvpragyrgivtfqfpgrrvhlappptwegydpwn\*

Gcgggtattcccatcctgggtcatcgcctgtgaccgcagcactgttcggcgcgatctagacaagctgctgcattatcgccctcggtg  
agctcttcccatcatcgttagccaggactgcgggcacgaggagacggcccaggccatcgctcctacggcagcgcggtcacgcac  
atccggcagcccgaactgagcagcattcggtgccgccggaccaccgcaagttccagggtactacaagatcgcgccactacc  
gctgggcgctgggccaggtcttccggcagtttcgttcccccgggccgtggtggtggaggatgacctggaggtggccccggacttct  
tcgagtactttcgggccacctatccgctgctgaaggccgacccctccctgtggtgcgtctcggcctggaatgacaacggcaaggagc  
agatggtggacgccagcaggcctgagctgctctaccgcaccgacttttccctggcctgggctggtgctgttggccgagctctggc  
tgagctggagcccaagtggccaaaggccttctgggacgactggatgcggcggccggagcagcggcagggggcgggcctgcatac  
gccctgagatctcaagaacgatgaccttggccgcaagggtgtgagccacgggcagttctttgaccagcacctcaagttatcaagctg  
aaccagcagtttgcacttcacccagctggacctgtcttacctgcagcgggaggcctatgaccgagatttcctcgccgcgtctacgg  
tgctccccagctgcaggtggagaaagtgaggaccaatgaccggaaggagctgggggaggtgcgggtgcagtatacgggcaggga  
cagcttcaaggcttcccaaggctctgggtgtcatggatgaccttaagtcgggggttccgagagctggctaccggggtattgtcacctt  
ccagttccggggccgcccgtgtccacctggcgccccaccgacgtgggagggtatgacctaagctggaattag

Figure 8

## GnT1 Cys121Thr

avipilviacdrstvrftldklhhyrpsaelfpfiivsqdcgheetaqaiasygsavthirqpdlssiavppdhrkfqgyykiarhyrwal  
gqvfrqfrfpaavvveddleavpddfeyfratypllkadpslwcvwsawndngkeqmvdasrpellyrtdffpglgwllaelwael  
epkwpkafwddwmrrpeqrqgracirpeisrtmtfgrkgvshgqffdqhlkfiklnqqfvhftqldlsylqreaydrdflarvyg  
apqlqvekvrtndrkelgevrqvtytgrdsfkafakalgvmddlksgvpragyrgivtfqfpgrrvhlappptwegydpwn\*

Gcgggtattcccatcctgggtcatcgccgtgaccgcagcactgttcggcgcaactctagacaagctgctgcattatcgccctcggctg  
agctcttcccatcatcggttagccaggactgcgggcacgaggagacggcccaggccatcgctcctacggcagcgcggtcacgcac  
atccggcagcccgaactgagcagcattcggtgccgccggaccaccgcaagttccagggtactacaagatcgcgcgccactacc  
gctgggcgctgggccaggtcttccggcagtttcgcttcccccgggccgtggtggtggaggatgacctggaggtggccccggacttct  
tcgagtactttcgggccacctatccgctgctgaaggccgacccctccctgtggtgcgtctcggcctggaatgacaacggcaaggagc  
agatggtggacgccagcaggcctgagctgctctaccgcaccgacttttccctggcctgggctggtgctgttgccgagctctggc  
tgagctggagcccaagtggccaaaggccttctgggacgactggatgcggcgccggagcagcggcagggggcggcctgcatac  
gccctgagatctcaagaacgatgacctttggccgcaagggtgtgagccacgggcagttctttgaccagcacctcaagttatcaagctg  
aaccagcagtttgacttcacccagctggacctgtctacctgcagcgggaggcctatgaccgagatttcctcgcccgcgtctacgg  
tgctccccagctgcaggtggagaaagtgaggaccaatgaccggaaggagctgggggaggtgcgggtgcagtatacgggcaggga  
cagcttcaaggcttcccaaggctctgggtgtcatggatgaccttaagtcgggggttcgagagctggctaccggggtattgtcacctt  
ccagttcccgggccgccgtgtccacctggcgccccaccgacgtgggagggctatgacctagctggaattag

Figure 9

## GnT1 Cys121Ala

avipilviacdrstvrraldkllhyrpsaelfpaiivsqdcgheetaqaiasygsavthirqpdlssiavppdhrkfqgyykiarhyrwa  
lgqvfrqfrfpaavvveddlevapdffeyfratypllkadpslwcv sawndngkeqmvdasrpellyrtdffpglgwlllaelwac  
lepkwpkafwddwmrrpeqrqgracirpeisrtmtfgrkgvshgqffdqhlkfiklnqqfvhftqldlsylqreaydrdflarvyg  
apqlqvekvrtndrkelgevrqvtytgrdsfkafakalgvmddlksgvpragyrgivtfqfpgrrvhlappptwegydpwn\*

Gcgggtattcccatcctgggtcatcgctgtgaccgcagcactgttcggcgccctagacaagctgctgcattatcgccctcggtg  
agctcttcccatcatcggttagccaggactgcgggcacgaggagacggcccaggccatcgctcctacggcagcgcggtcacgcac  
atccggcagcccagactgagcagcattcggtgccgccggaccaccgaagttccagggtactacaagatcgcgccactacc  
gctgggcgctgggccagggtcttcggcagtttcgttccccgcggccgtggtggtggaggatgacctggaggtggccccggacttct  
tcgagtactttcgggccacctatccgctgctgaaggccgacccctcctgtggtgcgtctcgccctggaatgacaacggcaaggagc  
agatggtggacgccagcaggcctgagctgctctaccgcaccgacttttccctggcctgggctggctgctgttgccgagctctgggc  
tgagctggagcccaagtggccaaaggccttctgggacgactggatgcggcgccggagcagcggcagggggcggcctgcatac  
gccctgagatctcaagaacgatgaccttggccgcaagggtgtgagccacgggcagttctttgaccagcacctcaagttatcaagctg  
aaccagcagtttgtgacttcacccagctggacctgtcttacctgcagcgggaggcctatgaccgagatttctcggcgcgtctacgg  
tgetccccagctgcaggtggagaaaagtgaggaccaatgaccggaaggagctgggggaggtgcgggtgcagtatacgggcaggga  
cagcttcaaggctttcccaaggctctgggtgtcatggatgaccttaagtcgggggttcgagagctggctaccggggtattgtcacctt  
ccagttccggggccgccgtgtccacctggcgccccaccgacgtgggagggtatgacctagctggaattag

Figure 10



## GnT1 Arg120Ala, Cys121H

avipilviacdrstv**ah**ldkllhyrpsaelfpiivs qdcgheetaqaiasygsavthirqpdlssiavppdhrkfqgyykiarhyrw  
algqvfrqfrfpaavvveddlevapdffeyfratypllkadpslwcvsawndngkeqmvdasrpellyrtdffpglgwillaelwa  
elepkwpkafwddwmrrpeqrqgracirpeisrtmtfgrkgvshgqffdqhlkfiklnqqfvhftqldsylqreaydrdflarvy  
gapqlqvekvrtndrkelgevrvtgrdsfkafakalgvmddlksgvpragyrgivtfqfpgrrvhlappptwegydpwn\*

Gcgggtattcccatcctgggtatcgcctgtgaccgcagcactgttcgggcccacctagacaagctgctgcattatcgccctcggtg  
agctcttcccatcatcgttagccaggactgcgggcacgaggagacggcccaggccatcgcctctacggcagcgcggtcacgcac  
atccggcagcccgaactgagcagcattgcgggtgccgccggaccaccgcaagttccagggtactacaagatcgcgcgccactacc  
gctgggcgctgggccaggtcttcggcagtttcgcttccccgcggccgtggtggaggatgacctggaggtggccccggacttct  
tcgagtactttcgggccacctatccgctgctgaaggccgacccctccctgtggtgcgtctcggcctggaatgacaacggcaaggagc  
agatggtggacgccagcaggcctgagctgctctaccgcaccgacttttccctggcctgggctggctgctgttggccgagctctgggc  
tgagctggagcccaagtggccaaaggccttctgggacgactggatgcggcggccggagcagcggcagggggcgggcctgcatac  
gccctgagatctcaagaacgatgacctttggccgcaagggtgtgagccacgggcagttctttgaccagcacctcaagttatcaagctg  
aaccagcagtttgcacttcaccagctggacctgtcttacctgcagcgggaggcctatgaccgagatttctcggccgcgtctacgg  
tgctccccagctgcaggtggagaaagtgaggaccaatgaccggaaggagctgggggaggtgcgggtgcagtatacgggcaggga  
cagcttcaaggcttcccaaggctctgggtgtcatggatgaccttaagtcgggggttcgagagctggctaccggggtattgtcacctt  
ccagttcccgggccgccgtgtccacctggcgccccaccgacgtgggagggctatgatcctagctggaattag

Figure 11

**Rat Liver ST3Gal III amino acid sequence:**

MGLLVFVRNLLLALCLFLVLGFLYSAWKLHLLQWEDSNSLILSLDSAGQTLGTEYDRL  
GFLCLKLDSKLPaelATKYANFSEGACKPGYASAMMTAIFPRFSKPAPMFLDDsFRKW  
ARIREFVPPFGIKGQDNLIKAILSvtKEYRLTPALDSLHCRRCIIVGNGGVLANKSLGS  
RIDdyDIVIRLNSAPVKGFEKDVGSKTTLRITYEGAMQRPEQYERDSLFLVLAGFKW  
QDFKWLKYIVYKERVSA SDGFWKSVATRPKEPPEIRILNPYFIQEAAFTLIGLPFNN  
GLMGRGNIPTLGSAVtMALDGCDEVAVAGFGYDMNTPNAPLHYyETVRMAAIKE  
SWTHNIQREKEFLRKLVKARVITDLSSGI

Figure 12

## **Application Data Sheet**

### **Application Information**

Application number::  
Filing Date:: 02/04/2004  
Application Type:: Provisional  
Subject Matter:: Utility  
Suggested classification::  
Suggested Group Art Unit::  
CD-ROM or CD-R??:  
Number of CD disks::  
Number of copies of CDs::  
Sequence Submission::  
Computer Readable Form (CRF)?::  
Number of copies of CRF::  
Title:: Method of Refolding Mammalian  
Glycosyltransferases  
Attorney Docket Number:: 019957-016800US  
Request for Early Publication:: No  
Request for Non-Publication:: No  
Suggested Drawing Figure::  
Total Drawing Sheets:: 12  
Small Entity?:: Yes  
Latin name::  
Variety denomination name::  
Petition included?:: No  
Petition Type::  
Licensed US Govt. Agency::  
Contract or Grant Numbers One::  
Secrecy Order in Parent Appl.:: No

**Applicant Information**

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Turkey  
Status:: Full Capacity  
Given Name:: Sami  
Middle Name::  
Family Name:: Saribas  
Name Suffix:: Ph.D.  
City of Residence:: Philadelphia  
State or Province of Residence:: PA  
Country of Residence:: US  
Street of Mailing Address:: 424 E. Church Lane  
City of Mailing Address:: Philadelphia  
State or Province of mailing address:: PA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 19144

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: David  
Middle Name::  
Family Name:: Hakes  
Name Suffix:: Ph.D.  
City of Residence:: Willow Grove  
State or Province of Residence:: PA  
Country of Residence:: US  
Street of Mailing Address:: 14 Fern Avenue  
City of Mailing Address:: Willow Grove  
State or Province of mailing address:: PA

Country of mailing address:: US  
Postal or Zip Code of mailing address:: 19090

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Scott  
Middle Name::  
Family Name:: Willett  
Name Suffix:: Ph.D.  
City of Residence:: Doylestown  
State or Province of Residence:: PA  
Country of Residence:: US  
Street of Mailing Address:: 3820 Comley Circle  
City of Mailing Address:: Doylestown  
State or Province of mailing address:: PA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 19801

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Karl  
Middle Name:: F.  
Family Name:: Johnson  
Name Suffix:: Ph.D.  
City of Residence:: Hatboro  
State or Province of Residence:: PA  
Country of Residence:: US  
Street of Mailing Address:: 5320 Ivystream Road  
City of Mailing Address:: Hatboro

State or Province of mailing address:: PA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 19040

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Daniel  
Middle Name:: J.  
Family Name:: Bezila  
Name Suffix::  
City of Residence:: Philadelphia  
State or Province of Residence:: PA  
Country of Residence:: US  
Street of Mailing Address:: 715 Red Lion Road, 2nd Floor  
City of Mailing Address:: Philadelphia  
State or Province of mailing address:: PA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 19115

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Shawn  
Middle Name::  
Family Name:: DeFrees  
Name Suffix::  
City of Residence:: North Wales  
State or Province of Residence:: PA  
Country of Residence:: US  
Street of Mailing Address:: 126 Filly Drive

City of Mailing Address:: North Wales  
State or Province of mailing address:: PA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 19454

**Correspondence Information**

Correspondence Customer Number:: 20350

**Representative Information**

Representative Customer Number:: 20350

**Domestic Priority Information**

Application:: Continuity Type:: Parent Application:: Parent Filing Date::

**Foreign Priority Information**

Country:: Application number:: Filing Date::

**Assignee Information**

Assignee Name::  
Street of mailing address::  
City of mailing address::  
State or Province of mailing address::  
Country of mailing address::  
Postal or Zip Code of mailing address::